AU2018344739B2 - Stereoselective process for preparing substituted polycyclic pyridone derivatives - Google Patents
Stereoselective process for preparing substituted polycyclic pyridone derivatives Download PDFInfo
- Publication number
- AU2018344739B2 AU2018344739B2 AU2018344739A AU2018344739A AU2018344739B2 AU 2018344739 B2 AU2018344739 B2 AU 2018344739B2 AU 2018344739 A AU2018344739 A AU 2018344739A AU 2018344739 A AU2018344739 A AU 2018344739A AU 2018344739 B2 AU2018344739 B2 AU 2018344739B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- formula
- group
- hydrogen
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- -1 polycyclic pyridone derivatives Chemical class 0.000 title claims abstract description 70
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 54
- 230000000707 stereoselective effect Effects 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims abstract description 273
- 238000006243 chemical reaction Methods 0.000 claims abstract description 73
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 28
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 141
- 239000000203 mixture Substances 0.000 claims description 133
- 229910052739 hydrogen Inorganic materials 0.000 claims description 109
- 125000001424 substituent group Chemical group 0.000 claims description 104
- 239000001257 hydrogen Substances 0.000 claims description 102
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 96
- 239000002904 solvent Substances 0.000 claims description 96
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 82
- 125000006239 protecting group Chemical group 0.000 claims description 72
- 238000000034 method Methods 0.000 claims description 62
- 125000000217 alkyl group Chemical group 0.000 claims description 46
- 150000003839 salts Chemical class 0.000 claims description 44
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 36
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 31
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 30
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 claims description 30
- 239000002253 acid Substances 0.000 claims description 24
- 229910052757 nitrogen Inorganic materials 0.000 claims description 23
- 125000003118 aryl group Chemical group 0.000 claims description 21
- 125000003277 amino group Chemical group 0.000 claims description 20
- 125000003545 alkoxy group Chemical group 0.000 claims description 19
- 229910052736 halogen Inorganic materials 0.000 claims description 19
- 150000002367 halogens Chemical class 0.000 claims description 19
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- 125000000623 heterocyclic group Chemical group 0.000 claims description 13
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- 239000007800 oxidant agent Substances 0.000 claims description 12
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 claims description 12
- 150000002443 hydroxylamines Chemical class 0.000 claims description 11
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 125000001188 haloalkyl group Chemical group 0.000 claims description 9
- 125000003282 alkyl amino group Chemical group 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- DQPBABKTKYNPMH-UHFFFAOYSA-N amino hydrogen sulfate Chemical group NOS(O)(=O)=O DQPBABKTKYNPMH-UHFFFAOYSA-N 0.000 claims description 7
- 230000002140 halogenating effect Effects 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 239000000654 additive Substances 0.000 claims description 6
- 230000000996 additive effect Effects 0.000 claims description 6
- 229910021529 ammonia Inorganic materials 0.000 claims description 6
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- SUKJFIGYRHOWBL-UHFFFAOYSA-N sodium hypochlorite Chemical group [Na+].Cl[O-] SUKJFIGYRHOWBL-UHFFFAOYSA-N 0.000 claims description 6
- 239000005708 Sodium hypochlorite Substances 0.000 claims description 5
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 5
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- 101100294102 Caenorhabditis elegans nhr-2 gene Proteins 0.000 claims description 4
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 claims description 4
- 125000005103 alkyl silyl group Chemical group 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 claims description 4
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 3
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 3
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 3
- 125000004414 alkyl thio group Chemical group 0.000 claims description 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 3
- 125000005844 heterocyclyloxy group Chemical group 0.000 claims description 3
- 125000004043 oxo group Chemical group O=* 0.000 claims description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 108010052300 RA X peptide Proteins 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- YKYONYBAUNKHLG-UHFFFAOYSA-N n-Propyl acetate Natural products CCCOC(C)=O YKYONYBAUNKHLG-UHFFFAOYSA-N 0.000 claims description 2
- 229940090181 propyl acetate Drugs 0.000 claims description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 5
- 101100416200 Caenorhabditis elegans rla-0 gene Proteins 0.000 claims 2
- 101100232295 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) GLK1 gene Proteins 0.000 claims 1
- 125000000524 functional group Chemical group 0.000 abstract description 22
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract description 9
- 230000002401 inhibitory effect Effects 0.000 abstract description 4
- 108010042407 Endonucleases Proteins 0.000 abstract description 3
- 230000001419 dependent effect Effects 0.000 abstract description 3
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 abstract description 3
- 102000004533 Endonucleases Human genes 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 93
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 86
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 58
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 55
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 51
- 230000002829 reductive effect Effects 0.000 description 38
- 239000000243 solution Substances 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 34
- SPEUIVXLLWOEMJ-UHFFFAOYSA-N 1,1-dimethoxyethane Chemical compound COC(C)OC SPEUIVXLLWOEMJ-UHFFFAOYSA-N 0.000 description 32
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 32
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 30
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- 239000012044 organic layer Substances 0.000 description 29
- 238000005160 1H NMR spectroscopy Methods 0.000 description 27
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 26
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 24
- 239000012299 nitrogen atmosphere Substances 0.000 description 24
- 230000035484 reaction time Effects 0.000 description 23
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 21
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 20
- 239000012046 mixed solvent Substances 0.000 description 20
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 19
- 150000001721 carbon Chemical group 0.000 description 19
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 18
- 239000013078 crystal Substances 0.000 description 18
- 239000011541 reaction mixture Substances 0.000 description 18
- 239000007787 solid Substances 0.000 description 18
- 239000010410 layer Substances 0.000 description 17
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 17
- 235000017557 sodium bicarbonate Nutrition 0.000 description 17
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 16
- 238000001816 cooling Methods 0.000 description 16
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 16
- MSXVEPNJUHWQHW-UHFFFAOYSA-N 2-methylbutan-2-ol Chemical compound CCC(C)(C)O MSXVEPNJUHWQHW-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 14
- 238000010898 silica gel chromatography Methods 0.000 description 14
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 12
- PAQZWJGSJMLPMG-UHFFFAOYSA-N 2,4,6-tripropyl-1,3,5,2$l^{5},4$l^{5},6$l^{5}-trioxatriphosphinane 2,4,6-trioxide Chemical compound CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 12
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical group BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 125000003367 polycyclic group Chemical group 0.000 description 12
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 12
- 238000003756 stirring Methods 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 229940098779 methanesulfonic acid Drugs 0.000 description 11
- 125000002950 monocyclic group Chemical group 0.000 description 11
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 10
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 10
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 10
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 10
- 239000003999 initiator Substances 0.000 description 10
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 150000003254 radicals Chemical class 0.000 description 10
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 10
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 9
- 235000011054 acetic acid Nutrition 0.000 description 9
- 239000003054 catalyst Substances 0.000 description 9
- 238000010511 deprotection reaction Methods 0.000 description 9
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- 238000000634 powder X-ray diffraction Methods 0.000 description 9
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 8
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 239000003638 chemical reducing agent Substances 0.000 description 8
- 229910000027 potassium carbonate Inorganic materials 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 150000002148 esters Chemical group 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 7
- XPCTZQVDEJYUGT-UHFFFAOYSA-N 3-hydroxy-2-methyl-4-pyrone Chemical compound CC=1OC=CC(=O)C=1O XPCTZQVDEJYUGT-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 229910052731 fluorine Inorganic materials 0.000 description 6
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- PFHOSZAOXCYAGJ-UHFFFAOYSA-N 2-[(2-cyano-4-methoxy-4-methylpentan-2-yl)diazenyl]-4-methoxy-2,4-dimethylpentanenitrile Chemical compound COC(C)(C)CC(C)(C#N)N=NC(C)(C#N)CC(C)(C)OC PFHOSZAOXCYAGJ-UHFFFAOYSA-N 0.000 description 5
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 5
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 5
- LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Substances IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 5
- KYIKRXIYLAGAKQ-UHFFFAOYSA-N abcn Chemical compound C1CCCCC1(C#N)N=NC1(C#N)CCCCC1 KYIKRXIYLAGAKQ-UHFFFAOYSA-N 0.000 description 5
- 239000007864 aqueous solution Substances 0.000 description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 5
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical compound BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 5
- 229940125773 compound 10 Drugs 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 5
- 229940011051 isopropyl acetate Drugs 0.000 description 5
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 5
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 5
- SKTCDJAMAYNROS-UHFFFAOYSA-N methoxycyclopentane Chemical compound COC1CCCC1 SKTCDJAMAYNROS-UHFFFAOYSA-N 0.000 description 5
- GDOPTJXRTPNYNR-UHFFFAOYSA-N methyl-cyclopentane Natural products CC1CCCC1 GDOPTJXRTPNYNR-UHFFFAOYSA-N 0.000 description 5
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 5
- ZIXXRXGPBFMPFD-UHFFFAOYSA-N 1-chloro-4-[(4-chlorophenyl)disulfanyl]benzene Chemical compound C1=CC(Cl)=CC=C1SSC1=CC=C(Cl)C=C1 ZIXXRXGPBFMPFD-UHFFFAOYSA-N 0.000 description 4
- VTSFNCCQCOEPKF-UHFFFAOYSA-N 3-amino-1h-pyridin-2-one Chemical compound NC1=CC=CN=C1O VTSFNCCQCOEPKF-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- ROFVEXUMMXZLPA-UHFFFAOYSA-N Bipyridyl Chemical class N1=CC=CC=C1C1=CC=CC=N1 ROFVEXUMMXZLPA-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 4
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 4
- 101000632319 Homo sapiens Septin-7 Proteins 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102100027981 Septin-7 Human genes 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 239000007874 V-70 Substances 0.000 description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 4
- 150000001299 aldehydes Chemical class 0.000 description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 4
- 150000001408 amides Chemical class 0.000 description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 4
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical compound FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000002425 crystallisation Methods 0.000 description 4
- 230000008025 crystallization Effects 0.000 description 4
- 239000012973 diazabicyclooctane Substances 0.000 description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 4
- 238000007429 general method Methods 0.000 description 4
- 239000000543 intermediate Chemical class 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 229910052751 metal Inorganic materials 0.000 description 4
- 239000002184 metal Substances 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 4
- 238000001228 spectrum Methods 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- 150000003573 thiols Chemical class 0.000 description 4
- IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 4
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- 239000004912 1,5-cyclooctadiene Substances 0.000 description 3
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 3
- ZPSJGADGUYYRKE-UHFFFAOYSA-N 2H-pyran-2-one Chemical class O=C1C=CC=CO1 ZPSJGADGUYYRKE-UHFFFAOYSA-N 0.000 description 3
- TXNLQUKVUJITMX-UHFFFAOYSA-N 4-tert-butyl-2-(4-tert-butylpyridin-2-yl)pyridine Chemical compound CC(C)(C)C1=CC=NC(C=2N=CC=C(C=2)C(C)(C)C)=C1 TXNLQUKVUJITMX-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 3
- 239000005695 Ammonium acetate Substances 0.000 description 3
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 239000007821 HATU Substances 0.000 description 3
- HYMLWHLQFGRFIY-UHFFFAOYSA-N Maltol Natural products CC1OC=CC(=O)C1=O HYMLWHLQFGRFIY-UHFFFAOYSA-N 0.000 description 3
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 3
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 3
- 235000019257 ammonium acetate Nutrition 0.000 description 3
- 229940043376 ammonium acetate Drugs 0.000 description 3
- 239000012141 concentrate Substances 0.000 description 3
- 239000010949 copper Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- WYACBZDAHNBPPB-UHFFFAOYSA-N diethyl oxalate Chemical compound CCOC(=O)C(=O)OCC WYACBZDAHNBPPB-UHFFFAOYSA-N 0.000 description 3
- HQWPLXHWEZZGKY-UHFFFAOYSA-N diethylzinc Chemical compound CC[Zn]CC HQWPLXHWEZZGKY-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 229940043353 maltol Drugs 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- PARWUHTVGZSQPD-UHFFFAOYSA-N phenylsilane Chemical compound [SiH3]C1=CC=CC=C1 PARWUHTVGZSQPD-UHFFFAOYSA-N 0.000 description 3
- NLKNQRATVPKPDG-UHFFFAOYSA-M potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 3
- 125000002577 pseudohalo group Chemical group 0.000 description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- JPJALAQPGMAKDF-UHFFFAOYSA-N selenium dioxide Chemical compound O=[Se]=O JPJALAQPGMAKDF-UHFFFAOYSA-N 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- ILMRJRBKQSSXGY-UHFFFAOYSA-N tert-butyl(dimethyl)silicon Chemical group C[Si](C)C(C)(C)C ILMRJRBKQSSXGY-UHFFFAOYSA-N 0.000 description 3
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 3
- 125000004665 trialkylsilyl group Chemical group 0.000 description 3
- LALRXNPLTWZJIJ-UHFFFAOYSA-N triethylborane Chemical compound CCB(CC)CC LALRXNPLTWZJIJ-UHFFFAOYSA-N 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- ASGMFNBUXDJWJJ-JLCFBVMHSA-N (1R,3R)-3-[[3-bromo-1-[4-(5-methyl-1,3,4-thiadiazol-2-yl)phenyl]pyrazolo[3,4-d]pyrimidin-6-yl]amino]-N,1-dimethylcyclopentane-1-carboxamide Chemical compound BrC1=NN(C2=NC(=NC=C21)N[C@H]1C[C@@](CC1)(C(=O)NC)C)C1=CC=C(C=C1)C=1SC(=NN=1)C ASGMFNBUXDJWJJ-JLCFBVMHSA-N 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 2
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 2
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 2
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
- UDQTXCHQKHIQMH-KYGLGHNPSA-N (3ar,5s,6s,7r,7ar)-5-(difluoromethyl)-2-(ethylamino)-5,6,7,7a-tetrahydro-3ah-pyrano[3,2-d][1,3]thiazole-6,7-diol Chemical compound S1C(NCC)=N[C@H]2[C@@H]1O[C@H](C(F)F)[C@@H](O)[C@@H]2O UDQTXCHQKHIQMH-KYGLGHNPSA-N 0.000 description 2
- HUWSZNZAROKDRZ-RRLWZMAJSA-N (3r,4r)-3-azaniumyl-5-[[(2s,3r)-1-[(2s)-2,3-dicarboxypyrrolidin-1-yl]-3-methyl-1-oxopentan-2-yl]amino]-5-oxo-4-sulfanylpentane-1-sulfonate Chemical compound OS(=O)(=O)CC[C@@H](N)[C@@H](S)C(=O)N[C@@H]([C@H](C)CC)C(=O)N1CCC(C(O)=O)[C@H]1C(O)=O HUWSZNZAROKDRZ-RRLWZMAJSA-N 0.000 description 2
- YQOLEILXOBUDMU-KRWDZBQOSA-N (4R)-5-[(6-bromo-3-methyl-2-pyrrolidin-1-ylquinoline-4-carbonyl)amino]-4-(2-chlorophenyl)pentanoic acid Chemical compound CC1=C(C2=C(C=CC(=C2)Br)N=C1N3CCCC3)C(=O)NC[C@H](CCC(=O)O)C4=CC=CC=C4Cl YQOLEILXOBUDMU-KRWDZBQOSA-N 0.000 description 2
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- CYSGHNMQYZDMIA-UHFFFAOYSA-N 1,3-Dimethyl-2-imidazolidinon Chemical compound CN1CCN(C)C1=O CYSGHNMQYZDMIA-UHFFFAOYSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 2
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 2
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 2
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 2
- FQMZXMVHHKXGTM-UHFFFAOYSA-N 2-(1-adamantyl)-n-[2-[2-(2-hydroxyethylamino)ethylamino]quinolin-5-yl]acetamide Chemical compound C1C(C2)CC(C3)CC2CC13CC(=O)NC1=CC=CC2=NC(NCCNCCO)=CC=C21 FQMZXMVHHKXGTM-UHFFFAOYSA-N 0.000 description 2
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- WADSJYLPJPTMLN-UHFFFAOYSA-N 3-(cycloundecen-1-yl)-1,2-diazacycloundec-2-ene Chemical compound C1CCCCCCCCC=C1C1=NNCCCCCCCC1 WADSJYLPJPTMLN-UHFFFAOYSA-N 0.000 description 2
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 2
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 2
- BMTZEAOGFDXDAD-UHFFFAOYSA-M 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholin-4-ium;chloride Chemical compound [Cl-].COC1=NC(OC)=NC([N+]2(C)CCOCC2)=N1 BMTZEAOGFDXDAD-UHFFFAOYSA-M 0.000 description 2
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical class OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229910015900 BF3 Inorganic materials 0.000 description 2
- OJRUSAPKCPIVBY-KQYNXXCUSA-N C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N Chemical compound C1=NC2=C(N=C(N=C2N1[C@H]3[C@@H]([C@@H]([C@H](O3)COP(=O)(CP(=O)(O)O)O)O)O)I)N OJRUSAPKCPIVBY-KQYNXXCUSA-N 0.000 description 2
- BQXUPNKLZNSUMC-YUQWMIPFSA-N CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 Chemical compound CCN(CCCCCOCC(=O)N[C@H](C(=O)N1C[C@H](O)C[C@H]1C(=O)N[C@@H](C)c1ccc(cc1)-c1scnc1C)C(C)(C)C)CCOc1ccc(cc1)C(=O)c1c(sc2cc(O)ccc12)-c1ccc(O)cc1 BQXUPNKLZNSUMC-YUQWMIPFSA-N 0.000 description 2
- 229940126657 Compound 17 Drugs 0.000 description 2
- 229940127007 Compound 39 Drugs 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Natural products CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- GUUVPOWQJOLRAS-UHFFFAOYSA-N Diphenyl disulfide Chemical compound C=1C=CC=CC=1SSC1=CC=CC=C1 GUUVPOWQJOLRAS-UHFFFAOYSA-N 0.000 description 2
- 102100031780 Endonuclease Human genes 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229910021627 Tin(IV) chloride Inorganic materials 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- XAKBSHICSHRJCL-UHFFFAOYSA-N [CH2]C(=O)C1=CC=CC=C1 Chemical group [CH2]C(=O)C1=CC=CC=C1 XAKBSHICSHRJCL-UHFFFAOYSA-N 0.000 description 2
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 2
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical class C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 125000004644 alkyl sulfinyl group Chemical group 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- BCJCJALHNXSXKE-UHFFFAOYSA-N azado Chemical compound C1C(C2)CC3CC1N([O])C2C3 BCJCJALHNXSXKE-UHFFFAOYSA-N 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000005587 bubbling Effects 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 229940125797 compound 12 Drugs 0.000 description 2
- 229940125758 compound 15 Drugs 0.000 description 2
- 229940126142 compound 16 Drugs 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940125810 compound 20 Drugs 0.000 description 2
- 229940125846 compound 25 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 229940125877 compound 31 Drugs 0.000 description 2
- 229940127573 compound 38 Drugs 0.000 description 2
- 229940125936 compound 42 Drugs 0.000 description 2
- 229940125844 compound 46 Drugs 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- QTMDXZNDVAMKGV-UHFFFAOYSA-L copper(ii) bromide Chemical compound [Cu+2].[Br-].[Br-] QTMDXZNDVAMKGV-UHFFFAOYSA-L 0.000 description 2
- 238000007872 degassing Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 150000004985 diamines Chemical class 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- JAXFJECJQZDFJS-XHEPKHHKSA-N gtpl8555 Chemical compound OC(=O)C[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@@H]1C(=O)N[C@H](B1O[C@@]2(C)[C@H]3C[C@H](C3(C)C)C[C@H]2O1)CCC1=CC=C(F)C=C1 JAXFJECJQZDFJS-XHEPKHHKSA-N 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 238000009776 industrial production Methods 0.000 description 2
- 239000002198 insoluble material Substances 0.000 description 2
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- YNESATAKKCNGOF-UHFFFAOYSA-N lithium bis(trimethylsilyl)amide Chemical compound [Li+].C[Si](C)(C)[N-][Si](C)(C)C YNESATAKKCNGOF-UHFFFAOYSA-N 0.000 description 2
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 2
- LVWZTYCIRDMTEY-UHFFFAOYSA-N metamizole Chemical compound O=C1C(N(CS(O)(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 LVWZTYCIRDMTEY-UHFFFAOYSA-N 0.000 description 2
- YYTWEEOFRNSTKS-UHFFFAOYSA-N n,n'-dicyclohexylmethanediimine;1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1.C1CCCCC1N=C=NC1CCCCC1 YYTWEEOFRNSTKS-UHFFFAOYSA-N 0.000 description 2
- UJKUJXVZLUTEAZ-UHFFFAOYSA-N n,n-dimethylformamide;dimethyl sulfate Chemical compound CN(C)C=O.COS(=O)(=O)OC UJKUJXVZLUTEAZ-UHFFFAOYSA-N 0.000 description 2
- 125000001624 naphthyl group Chemical group 0.000 description 2
- PIDFDZJZLOTZTM-KHVQSSSXSA-N ombitasvir Chemical compound COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C([C@H]2N([C@@H](CC2)C=2C=CC(NC(=O)[C@H]3N(CCC3)C(=O)[C@@H](NC(=O)OC)C(C)C)=CC=2)C=2C=CC(=CC=2)C(C)(C)C)C=C1 PIDFDZJZLOTZTM-KHVQSSSXSA-N 0.000 description 2
- 235000006408 oxalic acid Nutrition 0.000 description 2
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000011941 photocatalyst Substances 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 2
- 235000019260 propionic acid Nutrition 0.000 description 2
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 2
- 229960002218 sodium chlorite Drugs 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- 125000003003 spiro group Chemical group 0.000 description 2
- KXCAEQNNTZANTK-UHFFFAOYSA-N stannane Chemical compound [SnH4] KXCAEQNNTZANTK-UHFFFAOYSA-N 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- NHGXDBSUJJNIRV-UHFFFAOYSA-M tetrabutylammonium chloride Chemical compound [Cl-].CCCC[N+](CCCC)(CCCC)CCCC NHGXDBSUJJNIRV-UHFFFAOYSA-M 0.000 description 2
- 229910000083 tin tetrahydride Inorganic materials 0.000 description 2
- HPGGPRDJHPYFRM-UHFFFAOYSA-J tin(iv) chloride Chemical compound Cl[Sn](Cl)(Cl)Cl HPGGPRDJHPYFRM-UHFFFAOYSA-J 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- SCHZCUMIENIQMY-UHFFFAOYSA-N tris(trimethylsilyl)silicon Chemical compound C[Si](C)(C)[Si]([Si](C)(C)C)[Si](C)(C)C SCHZCUMIENIQMY-UHFFFAOYSA-N 0.000 description 2
- CXNIUSPIQKWYAI-UHFFFAOYSA-N xantphos Chemical compound C=12OC3=C(P(C=4C=CC=CC=4)C=4C=CC=CC=4)C=CC=C3C(C)(C)C2=CC=CC=1P(C=1C=CC=CC=1)C1=CC=CC=C1 CXNIUSPIQKWYAI-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- FHOAKXBXYSJBGX-YFKPBYRVSA-N (2s)-3-hydroxy-2-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CO)C(O)=O FHOAKXBXYSJBGX-YFKPBYRVSA-N 0.000 description 1
- STBLNCCBQMHSRC-BATDWUPUSA-N (2s)-n-[(3s,4s)-5-acetyl-7-cyano-4-methyl-1-[(2-methylnaphthalen-1-yl)methyl]-2-oxo-3,4-dihydro-1,5-benzodiazepin-3-yl]-2-(methylamino)propanamide Chemical compound O=C1[C@@H](NC(=O)[C@H](C)NC)[C@H](C)N(C(C)=O)C2=CC(C#N)=CC=C2N1CC1=C(C)C=CC2=CC=CC=C12 STBLNCCBQMHSRC-BATDWUPUSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LFKXWKGYHQXRQA-FDGPNNRMSA-N (z)-4-hydroxypent-3-en-2-one;iron Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LFKXWKGYHQXRQA-FDGPNNRMSA-N 0.000 description 1
- POILWHVDKZOXJZ-ARJAWSKDSA-M (z)-4-oxopent-2-en-2-olate Chemical compound C\C([O-])=C\C(C)=O POILWHVDKZOXJZ-ARJAWSKDSA-M 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 1
- FTTATHOUSOIFOQ-UHFFFAOYSA-N 1,2,3,4,6,7,8,8a-octahydropyrrolo[1,2-a]pyrazine Chemical compound C1NCCN2CCCC21 FTTATHOUSOIFOQ-UHFFFAOYSA-N 0.000 description 1
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- VYXHVRARDIDEHS-UHFFFAOYSA-N 1,5-cyclooctadiene Chemical compound C1CC=CCCC=C1 VYXHVRARDIDEHS-UHFFFAOYSA-N 0.000 description 1
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 1
- HLVFKOKELQSXIQ-UHFFFAOYSA-N 1-bromo-2-methylpropane Chemical compound CC(C)CBr HLVFKOKELQSXIQ-UHFFFAOYSA-N 0.000 description 1
- MNDIARAMWBIKFW-UHFFFAOYSA-N 1-bromohexane Chemical compound CCCCCCBr MNDIARAMWBIKFW-UHFFFAOYSA-N 0.000 description 1
- WGCYRFWNGRMRJA-UHFFFAOYSA-N 1-ethylpiperazine Chemical compound CCN1CCNCC1 WGCYRFWNGRMRJA-UHFFFAOYSA-N 0.000 description 1
- PJUPKRYGDFTMTM-UHFFFAOYSA-N 1-hydroxybenzotriazole;hydrate Chemical compound O.C1=CC=C2N(O)N=NC2=C1 PJUPKRYGDFTMTM-UHFFFAOYSA-N 0.000 description 1
- ANOOTOPTCJRUPK-UHFFFAOYSA-N 1-iodohexane Chemical compound CCCCCCI ANOOTOPTCJRUPK-UHFFFAOYSA-N 0.000 description 1
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- LULZXNOVLBISGB-UHFFFAOYSA-N 10-methyl-9-(2,4,6-trimethylphenyl)acridin-10-ium Chemical class CC1=CC(C)=CC(C)=C1C1=C(C=CC=C2)C2=[N+](C)C2=CC=CC=C12 LULZXNOVLBISGB-UHFFFAOYSA-N 0.000 description 1
- RSHPQBYMCLMJOU-UHFFFAOYSA-N 11-hydroxy-5-oxa-1,2,8-triazatricyclo[8.4.0.03,8]tetradeca-10,13-diene-9,12-dione Chemical compound Oc1c2C(=O)N3CCOCC3Nn2ccc1=O RSHPQBYMCLMJOU-UHFFFAOYSA-N 0.000 description 1
- YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
- YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
- OZQVMCWRPVWJTF-UHFFFAOYSA-N 2,7,10-trimethyl-9-(2,4,6-trimethylphenyl)acridin-10-ium Chemical class C12=CC(C)=CC=C2[N+](C)=C2C=CC(C)=CC2=C1C1=C(C)C=C(C)C=C1C OZQVMCWRPVWJTF-UHFFFAOYSA-N 0.000 description 1
- ZWCNYHCXTYJJNJ-UHFFFAOYSA-N 2-(4-carbamoylpyridin-2-yl)pyridine-4-carboxamide Chemical compound NC(=O)C1=CC=NC(C=2N=CC=C(C=2)C(N)=O)=C1 ZWCNYHCXTYJJNJ-UHFFFAOYSA-N 0.000 description 1
- FXPLCAKVOYHAJA-UHFFFAOYSA-N 2-(4-carboxypyridin-2-yl)pyridine-4-carboxylic acid Chemical compound OC(=O)C1=CC=NC(C=2N=CC=C(C=2)C(O)=O)=C1 FXPLCAKVOYHAJA-UHFFFAOYSA-N 0.000 description 1
- IUMFOUVCDJGKNS-UHFFFAOYSA-N 2-(4-cyanopyridin-2-yl)pyridine-4-carbonitrile Chemical compound N#CC1=CC=NC(C=2N=CC=C(C=2)C#N)=C1 IUMFOUVCDJGKNS-UHFFFAOYSA-N 0.000 description 1
- PYRKKGOKRMZEIT-UHFFFAOYSA-N 2-[6-(2-cyclopropylethoxy)-9-(2-hydroxy-2-methylpropyl)-1h-phenanthro[9,10-d]imidazol-2-yl]-5-fluorobenzene-1,3-dicarbonitrile Chemical compound C1=C2C3=CC(CC(C)(O)C)=CC=C3C=3NC(C=4C(=CC(F)=CC=4C#N)C#N)=NC=3C2=CC=C1OCCC1CC1 PYRKKGOKRMZEIT-UHFFFAOYSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- UYCUMNRCCJNSBR-UHFFFAOYSA-N 2-ethoxy-2-oxoacetic acid;hydrochloride Chemical compound Cl.CCOC(=O)C(O)=O UYCUMNRCCJNSBR-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- LJMSAUILRDVXCA-UHFFFAOYSA-N 2-methoxy-2-oxoacetic acid;hydrochloride Chemical compound Cl.COC(=O)C(O)=O LJMSAUILRDVXCA-UHFFFAOYSA-N 0.000 description 1
- HAJMXMJHEZUCJW-UHFFFAOYSA-N 2-methylpropyl 2-[4-(2-methylpropoxycarbonyl)pyridin-2-yl]pyridine-4-carboxylate Chemical compound CC(C)COC(=O)c1ccnc(c1)-c1cc(ccn1)C(=O)OCC(C)C HAJMXMJHEZUCJW-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- QDFXRVAOBHEBGJ-UHFFFAOYSA-N 3-(cyclononen-1-yl)-4,5,6,7,8,9-hexahydro-1h-diazonine Chemical compound C1CCCCCCC=C1C1=NNCCCCCC1 QDFXRVAOBHEBGJ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LOKDIDVKVVVVHK-UHFFFAOYSA-N 3-hydroxy-4-methyl-1,3-thiazole-2-thione Chemical compound CC1=CSC(=S)N1O LOKDIDVKVVVVHK-UHFFFAOYSA-N 0.000 description 1
- XCMRHOMYGPXALN-UHFFFAOYSA-N 4-(bromomethyl)-2-[4-(bromomethyl)pyridin-2-yl]pyridine Chemical compound BrCC1=CC=NC(C=2N=CC=C(CBr)C=2)=C1 XCMRHOMYGPXALN-UHFFFAOYSA-N 0.000 description 1
- OQVYMXCRDHDTTH-UHFFFAOYSA-N 4-(diethoxyphosphorylmethyl)-2-[4-(diethoxyphosphorylmethyl)pyridin-2-yl]pyridine Chemical compound CCOP(=O)(OCC)CC1=CC=NC(C=2N=CC=C(CP(=O)(OCC)OCC)C=2)=C1 OQVYMXCRDHDTTH-UHFFFAOYSA-N 0.000 description 1
- IMEVSAIFJKKDAP-UHFFFAOYSA-N 4-methoxy-2-(4-methoxypyridin-2-yl)pyridine Chemical compound COC1=CC=NC(C=2N=CC=C(OC)C=2)=C1 IMEVSAIFJKKDAP-UHFFFAOYSA-N 0.000 description 1
- UQRONKZLYKUEMO-UHFFFAOYSA-N 4-methyl-1-(2,4,6-trimethylphenyl)pent-4-en-2-one Chemical group CC(=C)CC(=O)Cc1c(C)cc(C)cc1C UQRONKZLYKUEMO-UHFFFAOYSA-N 0.000 description 1
- NBPGPQJFYXNFKN-UHFFFAOYSA-N 4-methyl-2-(4-methylpyridin-2-yl)pyridine Chemical compound CC1=CC=NC(C=2N=CC=C(C)C=2)=C1 NBPGPQJFYXNFKN-UHFFFAOYSA-N 0.000 description 1
- VHJFWJXYEWHCGD-UHFFFAOYSA-N 4-nonyl-2-(4-nonylpyridin-2-yl)pyridine Chemical compound CCCCCCCCCC1=CC=NC(C=2N=CC=C(CCCCCCCCC)C=2)=C1 VHJFWJXYEWHCGD-UHFFFAOYSA-N 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000005046 Chlorosilane Substances 0.000 description 1
- 229910019131 CoBr2 Inorganic materials 0.000 description 1
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 1
- 229910021584 Cobalt(II) iodide Inorganic materials 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 description 1
- 229910021591 Copper(I) chloride Inorganic materials 0.000 description 1
- 229910021590 Copper(II) bromide Inorganic materials 0.000 description 1
- 229910021592 Copper(II) chloride Inorganic materials 0.000 description 1
- 229910016523 CuKa Inorganic materials 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910021575 Iron(II) bromide Inorganic materials 0.000 description 1
- 229910021577 Iron(II) chloride Inorganic materials 0.000 description 1
- 229910021579 Iron(II) iodide Inorganic materials 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- LOMVENUNSWAXEN-UHFFFAOYSA-N Methyl oxalate Chemical compound COC(=O)C(=O)OC LOMVENUNSWAXEN-UHFFFAOYSA-N 0.000 description 1
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 229910021585 Nickel(II) bromide Inorganic materials 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- HJTRSKVIYMCKJU-UHFFFAOYSA-N O=C1C=CN2NC3COCCN3C(=O)C2=C1OCC1=CC=CC=C1 Chemical compound O=C1C=CN2NC3COCCN3C(=O)C2=C1OCC1=CC=CC=C1 HJTRSKVIYMCKJU-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 101100028962 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDR1 gene Proteins 0.000 description 1
- 229910018162 SeO2 Inorganic materials 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
- PSLUFJFHTBIXMW-WYEYVKMPSA-N [(3r,4ar,5s,6s,6as,10s,10ar,10bs)-3-ethenyl-10,10b-dihydroxy-3,4a,7,7,10a-pentamethyl-1-oxo-6-(2-pyridin-2-ylethylcarbamoyloxy)-5,6,6a,8,9,10-hexahydro-2h-benzo[f]chromen-5-yl] acetate Chemical compound O([C@@H]1[C@@H]([C@]2(O[C@](C)(CC(=O)[C@]2(O)[C@@]2(C)[C@@H](O)CCC(C)(C)[C@@H]21)C=C)C)OC(=O)C)C(=O)NCCC1=CC=CC=N1 PSLUFJFHTBIXMW-WYEYVKMPSA-N 0.000 description 1
- RRXGRDMHWYLJSY-UHFFFAOYSA-N [2-[4-(hydroxymethyl)pyridin-2-yl]pyridin-4-yl]methanol Chemical compound OCC1=CC=NC(C=2N=CC=C(CO)C=2)=C1 RRXGRDMHWYLJSY-UHFFFAOYSA-N 0.000 description 1
- ASHMBQUGLGIKAT-UHFFFAOYSA-L [Li+].[OH-].[OH-].[K+] Chemical compound [Li+].[OH-].[OH-].[K+] ASHMBQUGLGIKAT-UHFFFAOYSA-L 0.000 description 1
- 150000001241 acetals Chemical class 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- CUJRVFIICFDLGR-UHFFFAOYSA-N acetylacetonate Chemical compound CC(=O)[CH-]C(C)=O CUJRVFIICFDLGR-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 150000001356 alkyl thiols Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 125000005428 anthryl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C3C(*)=C([H])C([H])=C([H])C3=C([H])C2=C1[H] 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 125000002393 azetidinyl group Chemical group 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 229910052788 barium Inorganic materials 0.000 description 1
- DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 125000002619 bicyclic group Chemical group 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- MFSHZGFPADYOTO-UHFFFAOYSA-N chloromethyl methyl carbonate Chemical compound COC(=O)OCCl MFSHZGFPADYOTO-UHFFFAOYSA-N 0.000 description 1
- KOPOQZFJUQMUML-UHFFFAOYSA-N chlorosilane Chemical compound Cl[SiH3] KOPOQZFJUQMUML-UHFFFAOYSA-N 0.000 description 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- AVWLPUQJODERGA-UHFFFAOYSA-L cobalt(2+);diiodide Chemical compound [Co+2].[I-].[I-] AVWLPUQJODERGA-UHFFFAOYSA-L 0.000 description 1
- BKFAZDGHFACXKY-UHFFFAOYSA-N cobalt(II) bis(acetylacetonate) Chemical compound [Co+2].CC(=O)[CH-]C(C)=O.CC(=O)[CH-]C(C)=O BKFAZDGHFACXKY-UHFFFAOYSA-N 0.000 description 1
- FJDJVBXSSLDNJB-LNTINUHCSA-N cobalt;(z)-4-hydroxypent-3-en-2-one Chemical compound [Co].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O FJDJVBXSSLDNJB-LNTINUHCSA-N 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940125878 compound 36 Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- OXBLHERUFWYNTN-UHFFFAOYSA-M copper(I) chloride Chemical compound [Cu]Cl OXBLHERUFWYNTN-UHFFFAOYSA-M 0.000 description 1
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001047 cyclobutenyl group Chemical group C1(=CCC1)* 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001162 cycloheptenyl group Chemical group C1(=CCCCCC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000006547 cyclononyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000298 cyclopropenyl group Chemical group [H]C1=C([H])C1([H])* 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 125000004987 dibenzofuryl group Chemical group C1(=CC=CC=2OC3=C(C21)C=CC=C3)* 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 description 1
- 125000005056 dihydrothiazolyl group Chemical group S1C(NC=C1)* 0.000 description 1
- BADXJIPKFRBFOT-UHFFFAOYSA-N dimedone Chemical compound CC1(C)CC(=O)CC(=O)C1 BADXJIPKFRBFOT-UHFFFAOYSA-N 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 238000003708 edge detection Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004634 hexahydroazepinyl group Chemical group N1(CCCCCC1)* 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- QWPPOHNGKGFGJK-UHFFFAOYSA-N hypochlorous acid Chemical compound ClO QWPPOHNGKGFGJK-UHFFFAOYSA-N 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 125000005945 imidazopyridyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- GYCHYNMREWYSKH-UHFFFAOYSA-L iron(ii) bromide Chemical compound [Fe+2].[Br-].[Br-] GYCHYNMREWYSKH-UHFFFAOYSA-L 0.000 description 1
- BQZGVMWPHXIKEQ-UHFFFAOYSA-L iron(ii) iodide Chemical compound [Fe+2].[I-].[I-] BQZGVMWPHXIKEQ-UHFFFAOYSA-L 0.000 description 1
- LZKLAOYSENRNKR-LNTINUHCSA-N iron;(z)-4-oxoniumylidenepent-2-en-2-olate Chemical compound [Fe].C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O.C\C(O)=C\C(C)=O LZKLAOYSENRNKR-LNTINUHCSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000005929 isobutyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])OC(*)=O 0.000 description 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 150000002527 isonitriles Chemical class 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 229960003194 meglumine Drugs 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 1
- HBWBVIDKBKOVEX-UHFFFAOYSA-N methyl 2-(4-methoxycarbonylpyridin-2-yl)pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC(C=2N=CC=C(C=2)C(=O)OC)=C1 HBWBVIDKBKOVEX-UHFFFAOYSA-N 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- IOMMMLWIABWRKL-WUTDNEBXSA-N nazartinib Chemical compound C1N(C(=O)/C=C/CN(C)C)CCCC[C@H]1N1C2=C(Cl)C=CC=C2N=C1NC(=O)C1=CC=NC(C)=C1 IOMMMLWIABWRKL-WUTDNEBXSA-N 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- GWWNCLHJCFNTJA-UHFFFAOYSA-N nicandrenone-2 Natural products C12OC2C2(O)CC=CC(=O)C2(C)C(CCC23C)C1C3CCC2(O)C(C)C1OC(O)C2(C)OC2(C)C1 GWWNCLHJCFNTJA-UHFFFAOYSA-N 0.000 description 1
- LAIZPRYFQUWUBN-UHFFFAOYSA-L nickel chloride hexahydrate Chemical compound O.O.O.O.O.O.[Cl-].[Cl-].[Ni+2] LAIZPRYFQUWUBN-UHFFFAOYSA-L 0.000 description 1
- BMGNSKKZFQMGDH-FDGPNNRMSA-L nickel(2+);(z)-4-oxopent-2-en-2-olate Chemical compound [Ni+2].C\C([O-])=C\C(C)=O.C\C([O-])=C\C(C)=O BMGNSKKZFQMGDH-FDGPNNRMSA-L 0.000 description 1
- IPLJNQFXJUCRNH-UHFFFAOYSA-L nickel(2+);dibromide Chemical compound [Ni+2].[Br-].[Br-] IPLJNQFXJUCRNH-UHFFFAOYSA-L 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000005580 one pot reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000005880 oxathiolanyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000003551 oxepanyl group Chemical group 0.000 description 1
- 125000003566 oxetanyl group Chemical group 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 125000005954 phenoxathiinyl group Chemical group 0.000 description 1
- 125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- ACVYVLVWPXVTIT-UHFFFAOYSA-N phosphinic acid Chemical compound O[PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-N 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000005936 piperidyl group Chemical group 0.000 description 1
- 125000005575 polycyclic aromatic hydrocarbon group Chemical group 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- 239000012286 potassium permanganate Substances 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 150000003222 pyridines Chemical class 0.000 description 1
- ITFBHIXXJXZODU-UHFFFAOYSA-N pyrido[2,1-f][1,2,4]triazine-6,8-dione Chemical compound N=1N2C(C=NC=1)=CC(CC2=O)=O ITFBHIXXJXZODU-UHFFFAOYSA-N 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000001422 pyrrolinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- CGRKYEALWSRNJS-UHFFFAOYSA-N sodium;2-methylbutan-2-olate Chemical compound [Na+].CCC(C)(C)[O-] CGRKYEALWSRNJS-UHFFFAOYSA-N 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000003463 sulfur Chemical class 0.000 description 1
- DKACXUFSLUYRFU-UHFFFAOYSA-N tert-butyl n-aminocarbamate Chemical compound CC(C)(C)OC(=O)NN DKACXUFSLUYRFU-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- MCZDHTKJGDCTAE-UHFFFAOYSA-M tetrabutylazanium;acetate Chemical compound CC([O-])=O.CCCC[N+](CCCC)(CCCC)CCCC MCZDHTKJGDCTAE-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005942 tetrahydropyridyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- 125000005458 thianyl group Chemical group 0.000 description 1
- 125000004305 thiazinyl group Chemical group S1NC(=CC=C1)* 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000001730 thiiranyl group Chemical group 0.000 description 1
- 125000001166 thiolanyl group Chemical group 0.000 description 1
- 125000005505 thiomorpholino group Chemical group 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 239000013638 trimer Substances 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229910000406 trisodium phosphate Inorganic materials 0.000 description 1
- 235000019801 trisodium phosphate Nutrition 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
- C07C217/08—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- C07D309/40—Oxygen atoms attached in positions 3 and 4, e.g. maltol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Pyridine Compounds (AREA)
- Pyrane Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
The present invention provides a commercially applicable method for producing an intermediate of a substituted polycyclic pyridone derivative exhibiting cap-dependent endonuclease inhibitory activity. In the production method shown in the reaction formula (in the formula, the symbols are as defined in the description), by means of an intramolecular cyclisation reaction in which the stereochemistry of a compound shown in formula (III) or formula (VI) is controlled, a compound shown in formula (IV) and including an eliminable functional group on an asymmetric carbon is obtained, and said eliminable functional group is eliminated, whereby an optically active substituted 3-ring pyridone derivative shown in formula (VII) is highly enantioselectively obtained in a high yield.
Description
[0001] The present invention relates to a process for preparing substituted polycyclic pyridone derivatives. Specifically, the present invention relates to a stereoselective process for preparing substituted polycyclic pyridone derivatives and intermediates thereof.
[0002] It is known that a tricyclic pyridine derivatives such as 7-hydroxy-3,4,12,12a tetrahydro-1H-[1,4]oxazino[3,4-cpyrido[2,1-f][1,2,4]triazine-6,8-dione serves as a core skeleton of substituted polycyclic pyridone derivatives having cap-dependent endonuclease inhibitory activity and also as a common skeleton for other compounds useful as a medicament such as those compounds having HIV integrase inhibitory activity. Developments have been made to provide more industrially suitable methods for the synthesis of a common skeleton for such compounds useful as a medicament. Also, developments have been made to provide efficient methods for manufacturing a pyrone compound as a raw material for the production of such common skeleton.
[00031 Patent Documents 1 to 14 disclose a stereoselective process for preparing Doltegravir using (R)-aminoalcohol shown below. R Al o RAl o OH 0 RA' 4 O OJ R2 30RA4HO NH 2 R F N N N 0 2 RA RA3 RA2 H F 0 wherein RA I is hydroxyl, alkyloxy, halogen or the like; RA 2 is hydrogen, difluorobenzylcarbamoyl, alkyloxycarbonyl, carboxy or the like; RA is aldehyde or aldehyde equivalent; RA4 is alkyl or the like. Patent Document 15 and Non-Patent Document 1 disclose a stereoselective process for preparing Doltegravir and its derivatives using optically active aminoalcohol or diamine shown below. RA 6 RA6
OMe "" N NA N 5 RA5 "~N-z MO RAAH H x1 wherein RA 5 is difluorobenzylcarbamoyl; RA 6 is a protecting group for hydroxyl group; X1 is 0 or NRA 7 ; RA 7 is alkyl or the like; the other symbols are the same as defined above. Patent Document 16 and Non-Patent Document 2 disclose a process for preparing racemic Doltegravir derivatives using aminoalcohol or diamine shown below. OBn O OBn 0
S OMe N RA5 NX RA8 AOA R
wherein RA8I is hydrogen or difluorobenzylcarbamoyl; RA9 is hydrogen or two RA 9 may be taken together with an adjacent carbon atom to form carbocycle or heterocycle; the other symbols are the same as defined above. However, the above documents do not describe a process for preparing (R)-7 hydroxy-3,4,12,12a-tetrahydro-iH-[1,4]oxazino[3,4-cIpyrido[2,i-fl[1,2,4]triazine-6,8 dione.
[0004] Patent Document 17 discloses a process for preparing enantio mixture of 7 (benzyloxy)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][l,2,4]triazine 6,8-dione shown below. Wavy line means enantio mixture (1:1). OBn 0 OMe OBn 0
H0 OMe 0N 2 H
Patent Document 18 discloses a process for preparing the enantio mixture shown below. F OH O F OH O OH 0 0 O 0 N OH 0 N
S- N'N S N N'H 0 S N, N'N 1 N'N N-N O N-N
However, Patent Documents 17 and 18 do not describe a process for preparing optically active compound of 7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4 c]pyrido[2,1-fl[1,2,4]triazine-6,8-dione. Patent Documents 19 to 20 disclose a process that the enantio mixture of 7 (benzyloxy)-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine 6,8-dione, followed by optical resolution to give an optically active substance shown below. However, this process is not efficient because the compound having desired stereo configuration is obtained once the enantiomer mixture (1:1) is synthesized.
OBn 0
OBnO 0 O OBn O
0 '~NH 0 01 NN N'Alloc 'N H
OBn O OBn O
N OBn0
O 0'' O H 0 H 0 optical resolution
Also, Patent Documents 19 to 20 disclose a process for preparing 7-hydroxy 3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione which is substituted by methyl on the carbon adjacent to amide. After the introduction of Boc, the optically active compound is isolated and then deprotected to obtain the desired product. OMe OBn 0 OBn O NAlloc O0O CF OBn O
01 0 CF 3 0"NNH 01:__N HNH 2 NAlloc O
OBn O OBn O
00N N, N NO NN Boc H
However, there is neither description nor suggestion of anything for a stereoselective synthesis of 7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4 c]pyrido[2,1-f][1,2,4]triazine-6,8-dione by introducing a substituent on the carbon adjacent to amide. In addition, there is neither description nor suggestion of any process in which a substituent which can be removed is introduced and then the substituent is removed to obtain optically active compounds of 7-hydroxy-3,4,12,12a tetrahydro-1H-[1,4]oxazino[3,4-cpyrido[2,1-fl[1,2,4]triazine-6,8-dione. Patent Document 21 also discloses similar process, although it is unpublished at the priority date of the present application.
[00051 Patent Documents 3, 4. 22, 23 and Non-Patent Documents 3 to 7 disclose a process, as follows, for preparing a pyrone compound by direct oxidation of maltol.
However, selenium dioxide is a toxic reagent, and therefore, is not suitable for industrialproduction. OH Bns Bns 0 Bn O Me SeO2 ONaOCIO 0~~ N 0 OH -1 0~0N ~~N O Patent Documents 1 to 4 and 24 to 29 disclose a process, as follows, wherein the oxidateion of maltol is carried out via olefin. However, the process involves a reaction under low temperature at -70 0 C in the second step, and therefore, requires special equipment for industrial production.
OH Bn.. 1)LiHMDS OBn RuCl 3 OBn Bn, 0 O Me-NMe PhDHO NO Ph NaO OOH No2)DU NO NO N O H
Patent Documents 6, 18 and 30 to 36 disclose a process comprising condensation reaction as follows. However, these documents disclose examples only for a pyrone compound having ester, amide or hetero ring at a-position of the carbonyl group but not disclose a pyrone compound having hydrogen at a-position of the carbonyl group.
Bn, 0 OMe O Cl e Bn, O
MeO O OMe MeO NO N
[0006] Patent Document 19 disclose a process for the production of an aminopyridone compound, comprising direct reaction with Boc-hydrazine, as shown below.
Bn O BnN0 O BnN0 O
N OEt 0 N OEt e'N OEt o NHBoc N NH 2 Patent Document 5 discloses a process for the production of an aminopyridone compound via a pyridone, as shown below. The process differs from the process herein disclosed in that the side chain of the pyridone contains amide in the step to obtain aminopyridone.
Bn 0 O Bn 0 O Bn0 0 Bn0 0
PoA DcNH
Prior Art Documents
Patent Documents
[0007] Patent Document 1: W02010/011812 Patent Document 2: W02010/011819 Patent Document 3: W02010/068253 Patent Document 4: W02010/068262 Patent Document 5: W02010/110409 Patent Document 6: W02012/018065 Patent Document 7: W02014/128545 Patent Document 8: WO 2015/009927 Patent Document 9: WO 2015/019310 Patent Document 10: WO 2015/110897 Patent Document 11: WO 2015/111080 Patent Document 12: WO 2015/177537 Patent Document 13: WO 2016/092527 Patent Document 14: WO 2016/125192 Patent Document 15: WO 2006/116764 Patent Document 16: WO 2016/094198 Patent Document 17: WO 2012/039414 Patent Document 18: WO 2014/099586 Patent Document 19: WO 2016/175224 Patent Document 20: WO 2017/104691 Patent Document 21: PCT/JP2017/28923 Patent Document 22: WO 2006/116764 Patent Document 23: WO 2007/002109 Patent Document 24: WO 2010/011814 Patent Document 25: WO 2010/011815 Patent Document 26: WO 2010/011816 Patent Document 27: WO 2010/011818 Patent Document 28: WO 2010/067176 Patent Document 29: WO 2015/039348 Patent Document 30: WO 2011/105590 Patent Document 31: WO 2010/110409 Patent Document 32: WO 2010/147068 Patent Document 33: WO 2014/104279 Patent Document 34: WO 2015/095258 Patent Document 35: WO 2015/089847 Patent Document 36: WO 2015/199167
Non-Patent Documents
[0008] Non-Patent Document 1: Journal of Medicinal Chemistry, 2013, 56(14), 5901 5916 Non-Patent Document 2: Journal of Medicinal Chemistry, 2013, 56(3), 1124 1135 Non-Patent Document 3: Bioorganic & Medicinal Chemistry Letters, 2004,
14(12), 3257-3261 Non-Patent Document 4: Journal of Medicinal Chemistry, 2017, 60(8), 3498 3510 Non-Patent Document 5: Medicinal Chemistry Research, 2013, 22(5), 2351 2359 Non-Patent Document 6: ChemMedChem, 2008, 3(5), 812-820 Non-Patent Document 7: Medicinal Chemistry Research, 2013, 22(5), 2351 2359; 2013
[00091 The present invention provides an efficient method for preparing important intermediates for the production of substituted polycyclic pyridone derivatives, which are specifically a compound of the formula (VIII) or (IX) as disclosed herein or a salt thereof. Also, the present invention provides an efficient and more industrially suitable method for the production of a pyrone derivative and an aminopyridone derivative, as a raw material for the production of substituted polycyclic pyridone derivatives.
[0010] The present inventors have found efficient processes for the production of a compound of the formula (VII) which is an important intermediate for producing a compound of the formula (VIII) or (IX). That is, it has been found that an optically active tricyclic pyridone derivative of the formula (VII) can be obtained in a high yield with high enantioselectivity by intramolecular cyclization of a novel compound of the formula (III) or (VI) with controlled stereochemistry to obtain a novel compound of the formula (IV) having a removable functional group on an asymmetric carbon, and then removing the functional group. In addition, it has been found a process for the production of novel compounds of the formula (III) and (VI). Also, it has been found a novel process for the production of a compound of the formula (X3), (X8) or (V4).
[00111 That is, the present invention provides the following. (1) A process for preparing a compound of the formula (VII), or a salt thereof:
N (VIl)
N H H wherein R' is hydrogen or a protecting group for hydroxyl group; X is 0 or CH ; 2 characterized by removing -RA from a compound of the formula (IV):
RO 0 RAl
01 N RA2
H HRA 3 wherein R 1 is hydrogen or a protecting group for hydroxyl group; RAI is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is a removable functional group; and the carbon atom to which RA is bound is optically active; provided that one of RAI, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH, or RAI, RA2 and RA3 are hydrogen and X is CHRA.
(2) A process for preparing a compound of the formula (IV), or a salt thereof:
0 0 RA 1 RA 2
~N
wherein each symbol is as defined below characterized by subjecting a compound of the formula (III) to intramolecular cyclizationreaction: R1 0 RAl 0 2 O RA II
R A3 wherein R 1 is hydrogen or a protecting group for hydroxyl group; RAI is hydrogen or RA;RAS is hydrogen or RA; RAS is hydrogen or RA; X is 0, CH2 or CHRA; RA is a removable functional group and the carbon atom to which RA is bound is optically active; provided that one of RAI, RA2 and RAS is RA, the other two are hydrogen, and X is 0 or CH 2, or RAI, RA2 and RA6 are hydrogen and X is CHRA; RT is NH 2 or NHR2; R 2 is a protecting group for amino group; R 8 is -CHO or -CH(OR4)(OR4); R 4 is each independently hydrogen or a protecting group deprotectable by an acid, or two R 4 may be taken together to form a ring.
(3) The process for preparing the compound of the formula (VII) or a salt thereof according to (1), which comprises the process according to (2).
(4) The process according to (2) or (3), wherein the intramolecular cyclization reaction is carried out in the presence of an acid.
(5) A process for preparing a compound of the formula (III) or a salt thereof:
R1 0 0 RAl SA2R 8
RA3 wherein each symbol is as defined below characterized by reacting a compound of the formula (Ia): R1 *.O 0
OH 01 NN
wherein R' is hydrogen or a protecting group for hydroxyl group; R, is NH 2 or NHR 2; R 2 is a protecting group for amino group; with a compound of the formula (II): RAl RA 2 H 2N _ (1 X R8
RA 3 wherein RAI is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is a removable functional group and the carbon atom to which RA is bound is optically active; provided that one of RAI, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH2, or RAI, RA2 and RA3 are hydrogen and X is CHRA; R 8 is -CHO or -CH(OR4)(OR4); R 4 is each independently hydrogen or a protecting group deprotectable by an acid, or two R 4 may be taken together to form a ring.
(6) A process for preparing a compound of the formula (IV) or a salt thereof: R1 0 0 RAl O RA 2
H H RA 3 wherein each symbol is as defined below; characterized by subjecting a compound of the formula (VI) to intramolecular cyclizationreaction: R1 0 0
0 R3
R N (VI) RA3 RA N' x RAl RA 2 wherein RI is hydrogen or a protecting group for hydroxyl group; RAI is hydrogen or RA; RA2 is hydrogen or RA; RAS is hydrogen or RA; X is 0, CH 2 or CHRA; RA is a removable functional group and the carbon atom to which RA is bound is optically active; provided that one of RAI, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH 2, or R^1, RA2 and RA3 are hydrogen and X is CHRA; R 3 is a protecting group for carboxyl group; R 5 is hydrogen or a protecting group for amino group.
(7) The process for preparing the compound of the formula (VII) or a salt thereof according to (1), which comprises the process according to (6).
(8) The process according to (6) or (7), wherein the intramolecular cyclization reaction is carried out in the presence of a base.
(9) A process for preparing a compound of the formula (VI) or a salt thereof:
R i..0 0 0 O
NH (VI) N' 5 R RA
RA 2
wherein each symbol is as defined below; characterized by reacting a compound of the formula (Ib):
O'R3 (Ib) N.NH2
wherein RI is hydrogen or a protecting group for hydroxyl group; R 3 is a protecting group for carboxyl group; with a compound of the formula (V): O'R6 RA3 A N'R5 (V) X RAl 2 RA wherein R 5 is a protecting group for amino group; R 6 is substituted or unsubstituted alkyl, or substituted or unsubstituted aromatic carbocyclyl; R-l is hydrogen or RA; RA2 is hydrogen or RA; RA is hydrogen or RA X is 0, CH2 or CHRA; RA is a removable functional group and the carbon atom to which RA is bound is optically active; provided that one of RA, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH2, or RAI, RA2 and RAI are hydrogen and X is CHRA.
(10) The process according to any one of (1) to (9), wherein RAI is RA, and RA is optionally protected carboxy, or silyl-type functional group.
[00121 (11) A process for preparing a compound of the formula (X3) or a salt thereof:
R1 0
O' OH (X3) wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (X):
wherein Ria is a protecting group for hydroxyl group except optionally substituted aromatic carbocyclylalkyl and optionally substituted aromatic heterocyclylalkyl, with a halogenating agent to obtain a compound of the formula (X1):
R la
O' Z1 (X)
wherein Z' is halogen, and the other symbol is as defined above; (Step 2) reacting the compound of the formula (XI) with hydroxide ion to obtain a compound of the formula (X2):
O'z ''- OH (X2) 0 0
wherein each symbol is as defined above; and (Step 3) reacting the compound of the formula (X2) with an oxidizing agent to obtain the compound of the formula (X3).
(12) The process according to (11) wherein the halogenating agent is NBS, NCS, NIS, Br2, C1 2 , 12 or DBDMH, and the solvent in Step 1 is methyl acetate, ethyl acetate, propyl acetate or acetonitrile.
(13) The process according to (11) or (12) wherein the oxidizing agent-is sodium hypochlorite.
(14) A process for preparing a compound of the formula (X8) or a salt thereof:
R lb
,' 0 OH~ NO
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (X4):
R lbO
Oz (X4) wherein Rib is a protecting group for hydroxyl group, with a compound of the formula:
RB RB R( 1+ RD (X) 5N,RB or NsRB (X5')
RD RD wherein each RB is independently alkyl optionally substituted by a group selected from Substituent Group E, or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group E, or the two RB may be taken together with an adjacent nitrogen atom to form a heterocycle optionally substituted by a group selected from Substituent Group E; each RD is independently alkyloxy or dialkylamino; Substituent Group E comprises halogen, hydroxy, sulfanyl, amino, alkyl, haloalkyl, alkyloxy, alkylsulfanyl, alkylsilyl, aromatic carbocyclylsilyl optionally substituted by a group selected from Substituent Group F, carbocyclyl optionally substituted by a group selected from Substituent Group F, heterocyclyl optionally substituted by a group selected from Substituent Group F, a carbocyclylalkyloxy optionally substituted by a group selected from Substituent Group F, heterocyclylalkyloxy optionally substituted by a group selected from Substituent Group F, carbocyclylalkylsulfanyl optionally substituted by a group selected from Substituent Group F, heterocyclylalkylsulfanyl optionally substituted by a group selected from Substituent Group F, carbocyclylalkylamino optionally substituted by a group selected from Substituent Group F, heterocyclylalkylamino optionally substituted by a group selected from Substituent Group F, carbocyclyloxy optionally substituted by a group selected from Substituent Group F, heterocyclyloxy optionally substituted by a group selected from Substituent Group F, haloalkyloxy, alkyloxyalkyl, alkyloxyalkyloxy, alkyloxycarbonylamino, alkylamino, alkylcarbonylamino, alkylsulfonyl and alkylsulfonylamino; Substituent Group F comprises halogen, hydroxy, amino, oxo, nitro, alkyl, haloalkyl, alkyloxy and a protecting group for amino group; to obtain a compound of the formuala (X6):
RB (X6)
wherein each symbol is as defined above; (Step 2) reacting the compound of the formula (X6) with an oxidizing agent to obtain a compound of the formula (X7):
R b 0 o,
O 0
wherein each symbol is as defined above; and (Step 3) reacting the compound of the formula (X7) with an oxidizing agent to obtain the compound of the formula (X8).
(15) The process according to (14) wherein the Step 1 is carried out in the presence of a base.
(16) The process according to (14) or (15) wherein the oxidizing agent is sodium periodate.
(17) A process for preparing a compound of the formula (V4) or a salt thereof:
o 0 0, R3 (V4) S0
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (X9): R10 o (X9)
wherein RI is hydrogen or a protecting group for hydroxyl group, with a compound of the formula:
RC RC I I+ RD N,RC (V1) or N,Rc (V1')
wherein each R( is independently alkyl optionally substituted by a group selected from Substituent Group E, or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group E, or the two Rc may be taken together with an adjacent nitrogen atom to form a heterocycle optionally substituted by a group selected from Substituent Group E; each RD is independently alkyloxy or dialkylamino; Substituent Group E is as defined above in (14) to obtain a compound of the formula (V2):
c 0 R R1e (V2) N 0 RC wherein the wavy line represents E- or Z-form or a mixture thereof, and the other symbols are as defined above; (Step 2) subjecting the compound of the formula (V2) to intramolecular cyclization reaction by reacting with a compound of the formula (V3): 0
Z2 OR3 (V3) 0 wherein RIis alkyl optionally substituted by agroup selected from Substituent Group
E, aromatic carbocyclylalkyl optionally substituted by a group selected from Substituent Group B; and Z2 is hydrogen, halogen or alkyloxy optionally substituted by a group selected from Substituent Group E, to obtain a compound of the formula (V4).
(18) The process according to (17) wherein the Step 1 is carried out using DMSO as a solvent in the presence of an additive agent.
(19) The process according to (17) or (18) wherein the intramolecular cyclization reaction is carried out in the presence of an acid under anhydrous condition.
(20) A process for preparing a compound of the formula (V7) or a salt thereof:
O N H 0 R 3a (W) N N.NH2 wherein each symbol is as defined below, comprising reacting a compound of the formula (V6):
R 1, 0 0
O 'R 3 a (V6) NNH
wherein R 1 is hydrogen or a protecting group for hydroxyl group; and Ra is hydrogen or a protecting group for carboxyl group with a hydroxylamine derivative.
(21) A process for preparing a compound of the formula (V7) or a salt thereof:
O N -R 3a (V7)
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (V5):
R 1- 0 0
O'R 3a (V5) OR N0
wherein R' is hydrogen or a protecting group for hydroxyl group, and Raa is hydrogen or a protecting group for carboxyl group with ammonia to obtain a compound of the formula (V6
O'Raa (V6)
wherein each symbol is as defined above; and (Step 2) reacting the compound of the formula (V6) with a hydroxylamine derivative to obtain the compound of the formula (V7).
(22) The process according to (20) or (21), wherein the reaction with a hydroxylamine derivative is carried out in the presence of a base.
(23) The process according to (20) or (21), wherein the hydroxylamine derivative is hydroxylamine-0-sulfonic acid orO-(2,4-dinitrophenyl)hvdroxylamine.
(24) A process for preparing a compound of the formula (VIla) or the formula (IXa), or a salt thereof: 0 OH 0
N 0 N'N O N H N (Villa) N'N O (lXa)
F So r F H=H
F which comprises the process according to any one of (1) to (23).
(25) A compound of the formula (III) or a salt thereof: R1' 0 0 RA1
R A2 8 N 7H X - R8 3 RA wherein each symbol is as defined in (2).
(26) A compound of the formula (VI) or a salt thereof: R 1. 0 0
N3NH (VI) RA 3 R N'R5 X RA1 2 RA wherein each symbol is as defined in (6).
1A.
(27) A compound of the formula (IV) or a salt thereof:
R1O 0 RAl O RA 2
H RA 3 wherein each symbol is as defined in (1).
[00131 (28) A crystal of phosphate, methanesulfonate or p-chlorobenzoate salt of the compound of the formula: OMe
H2 N OMe
(29) The crystal according to (28) which is a crystal of the phosphate salt.
(30) The crystal according to (29) characterized by an X-ray powder diffraction spectrum comprising peaks at diffraction angle (20) of5.10±0.20, 15.30±0.20, 20.50±0.20, 25.7°±0.20 and 30.9±0.20.
(31) The crystal according to (29) characterized by an X-ray powder diffraction spectrum comprising peaks at diffraction angle (20) of 5.1±0.20, 10.2°±0.2°, 15.30±0.20, 20.50±0.20, 21.80±0.20, 25.7°A0.20, 30.90±0.20 and 36.3°±0.20.
(32) The crystal according to (29) characterized by an x-ray powder diffraction spectrum substantially in accordance with that shown in Figure 1.
[0014] The process of the present invention enables efficient production of a polycyclic pyridone derivative of the formula (VIII) or (IX) with high optical purity. One of the features of the present invention is that a carbon atom is substituted with RA, and then said RA is removed. A compound of the formula (IV) can be produced selectively by intramolecular cyclization using an optically active compound of the formula (III) or (VI). The selectivity is about 2 to 30 times. In particular, when RAI is RA, which is a protected carboxy, the compound of the formula (VI) can be prepared with a selectivity of about to 20 times.
Brief Description of Drawings
[0015] Fig.1 is an X-ray powder diffraction spectrum of the crystal of phosphate salt of Compound 26.
Mode for Carrying out the Invention
[0016] The meaning of each term used in the present description is explained below.
Unless otherwise specified, each term has the same meaning when used alone or in combination with another term. The term "consisting of" or "consists of" means that the named element(s) is included exclusively. The term "including", "include", "comprising" or "comprises" means to include, but not limited to, the named element(s), i.e., other element(s) is not excluded.
[00171 The term "optionally substituted by a group selected from Substituent Group A" means that any position may be substituted by one, two or more same or different groups selected from Substituent Group A. The same applies to the terms "optionally substituted by a group selected from Substituent Group B", "optionally substituted by a group selected from Substituent Group C", "optionally substituted by a group selected from Substituent Group D", "optionally substituted by a group selected from Substituent Group E" and "optionally substituted by a group selected from Substituent Group F". Substituent Group A: halogen, amino, alkylamino, alkylsulfonyl, aromatic carbocyclylsulfonyl, alkylsulfinyl, aromatic carbocyclylsulfinyl, nitro, alkyloxy, alkyloxycarbonyl, alkylcarbamoyl, and aromatic carbocyclyl. Substituent Group B: halogen, amino, alkylamino, alkylsulfonyl, aromatic carbocyclylsulfonyl, alkylsulfinyl, aromatic carbocyclylsulfinyl, nitro, alkyl, haloalkyl, alkyloxy, alkyloxycarbonyl, alkylcarbamoyl, and aromatic carbocyclyl. Substituent Group C: halogen, amino, alkylamino, alkyloxy, aromatic carbocyclyl. Substituent Group D: halogen, amino, alkylamino, alkyl, alkyloxy, and aromatic carbocyclylic group. Substituent Group E: halogen, hydroxy, sulfanyl, amino, alkyl, haloalkyl, alkyloxy, alkylsulfanyl, alkylsilyl, aromatic carbocyclylsilyl optionally substituted by a group selected from Substituent Group F, carbocyclyl optionally substituted by a group selected from Substituent Group F, heterocyclyl optionally substituted by a group selected from Substituent Group F, a carbocyclylalkyloxy optionally substituted by a group selected from Substituent Group F, heterocyclylalkyloxy optionally substituted by a group selected from Substituent Group F, carbocyclylalkylsulfanyl optionally substituted by a group selected from Substituent Group F, heterocyclylalkylsulfanyl optionally substituted by a group selected from Substituent Group F, carbocyclylalkylamino optionally substituted by a group selected from Substituent Group F, heterocyclylalkylamino optionally substituted by a group selected from Substituent Group F, carbocyclyloxy optionally substituted by a group selected from Substituent Group F, heterocyclyloxy optionally substituted by a group selected from Substituent Group F, haloalkyloxy, alkyloxyalkyl, alkyloxyalkyloxy, alkyloxycarbonylamino, alkylamino, alkylcarbonylamino, alkylsulfonyl, and alkylsulfonylamino. Substituent Group F: halogen, hydroxy, amino, oxo, nitro, alkyl, haloalkyl, alkyloxy, and a protecting group for amino group.
[0018] The term "halogen" includes fluorine, chlorine, bromine or iodine. Fluorine and chlorine are preferable, and fluorine is especially preferable.
[0019] The term "alkyl" means a C1 to C6 straight or branched alkyl and includes C1 to C4 alkyl, C1 to C3 alkyl and the like. Examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl, hexyl, isohexyl and the like. The term "substituted or unsubstituted alkyl" in R3 is not limited so long as it allows Step 3 of Scheme 5 in the general procedure described below to proceed efficiently. Examples include, but not limited to, alkyl optionally substituted by a group selected from Substituent Group A. The term "haloalkyl" means the above "alkyl" substituted with one or more "halogen" described above. Examples include trifluoromethyl, trifluoroethyl and the like. The term "alkylcarbamoyl" means a carbamoyl group substituted with one or two same or different "alkyl" described above on the nitrogen atom. Examples include methylcarbamoyl, ethylcarbamoyl, dimethylcarbamoyl, diethylcarbamoyl and the like. The term "alkylamino" means an amino group substituted with one or two same or different alkyll" described above on the nitrogen atom. Examples include methylamino, ethylamino, dimethylamino, diethylamino and the like. The term "alkylsilyl" means a group wherein one, two or three same or different "alkyl" described above issubstituted on the silyl. Examples include methylsilyl, ethylsilyl, dimethylsilyl, diethylsilyl, methylethylsilyl, trimethylsilyl and the like.
[0020] The term "carbocyclyl" means "aromatic carbocyclyl" or "non-aromatic carbocyclyl".
[0021] The term "carbocycle" means a ring derived from "carbocyclyl" described above.
[00221 The term "heterocyclyl" means "aromatic heterocyclyl" or "non-aromatic heterocyclyl".
[0023] The term "heterocycle" means a ring derived from "heterocyclyl" described above.
[0024] The term "aromatic carbocyclyl" means a monocyclic or polycyclic aromatic hydrocarbon group. Examples include phenyl, naphthyl, anthryl, phenanthryl and the like. A preferred embodiment of "aromatic carbocyclyl" is phenyl or naphtyl. The term "substituted or unsubstituted aromatic carbocyclyl" in R 6 is not limited so long as it allows Step 3 of Scheme 5 in the general procedure described below to proceed. Examples include, but not limited to, aromatic carbocyclyl optionally substituted by a group selected from Substituent Group B.
[00251
The term "aromatic carbocycle" means a ring derived from "aromatic carbocyclyl" described above.
[0026] The term "non-aromatic carbocyclyl" means a monocyclic or polycyclic saturated hydrocarbon group or unsaturated non-aromatic hydrocarbon group. The "non-aromatic carbocyclyl" which is polycyclic includes a fused ring group wherein a non-aromatic carbocyclyl, which is monocyclic or polycyclic, is fused with a ring of the above "aromatic carbocyclyl". In addition, examples of the "non-aromatic carbocyclyl" also include a group having a bridge or a group to form a spiro ring as follows:
The non-aromatic carbocyclyl which is monocyclic is preferably C3 to C16, more preferably C3 to C12 and further preferably C4 to C8 carbocyclyl. Examples include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, cyclononyl, cyclodecyl, cyclopropenyl, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl, cyclohexadienyl and the like. Examples of non-aromatic carbocyclyl, which is polycyclic, include indanyl, indenyl, acenaphthyl, tetrahydronaphthyl. fluorenyl and the like.
[0027] The term "non-aromatic carbocycle" means a ring derived from "non-aromatic carbocyclyl" described above.
[00281 The term "aromatic heterocyclyl" means an aromatic cyclyl, which is monocyclic or polycyclic, containing one or more, same or different heteroatom(s) selected independently from 0, S and N. The "aromatic heterocyclyl", which is polycyclic, includes a fused ring group wherein an aromatic heterocyclyl, which is monocyclic or polycyclic, is fused with a ring of the above "aromatic carbocyclyl". The free valency from the "heterocyclyl" may be on either ring. The aromatic heterocyclyl, which is monocyclic, is preferably 5- to 8 membered and more preferably 5- or 6-membered. Examples of 5-membered heterocyclyl include pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, furyl, thienyl, isoxazolyl, oxazolyl, oxadiazolyl, isothiazolyl, thiazolyl, thiadiazolyl and the like. Examples of 6-membered aromatic heterocyclyl include pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl and the like. The aromatic heterocyclyl, which is bicyclic, is preferably 8- to 10-membered and more preferably 9- or 10-membered. Examples include indolyl, isoindolyl, indazolyl, indolizinyl, quinolinyl, isoquinolinyl, cinnolinyl, phthalazinyl, quinazolinyl, naphthyridinyl, quinoxalinyl, purinyl, pteridinyl, benzimidazolyl, benzisoxazolyl, benzoxazolyl, benzoxadiazolyl, benzisothiazolyl, benzothiazolyl, benzothiadiazolyl, benzofuryl, isobenzofuryl, benzothienyl, benzotriazolyl, imidazopyridyl, triazolopyridyl, imidazothiazolyl, pyrazinopyridazinyl, oxazolopyridyl, thiazolopyridyl and the like. The aromatic heterocyclyl, which is tricyclic or more, is preferably 13- to 15 membered. Examples include carbazolyl, acridinyl, xanthenyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, dibenzofuryl and the like.
[0029] The term "aromatic heterocycle" means a ring derived from "aromatic heterocyclyl" described above.
[0030] The term "non-aromatic heterocyclyl" means a non-aromatic cyclyl, which is monocyclic or polycyclic, containing one or more, same or different heteroatom(s) selected independently from 0, S and N. The "non-aromatic heterocyclyl", which is polycyclic, include an above-mentioned non-aromatic heterocyclyl, which is monocyclic or polycyclic, fused with a ring of the above "aromatic carbocyclyl", "non aromatic carbocvclyl" and/or "aromatic heterocyclyl" and also include an above mentioned non-aromatic heterocyclyl, which is monocyclic or polycyclic, fused with a ring of the above "aromatic heterocyclyl", and the free valency may be on either ring. In addition, Examples of the "non-aromatic heterocyclyl" includes a group having a bridge or a group to form a spiro ring as follows: 0
N The non-aromatic heterocyclyl, which is monocyclic, is preferably 3- to 8 membered and more preferably 5- to 6-membered. Examples of non-aromatic heterocyclyl, which is 3-membered, include thiiranyl, oxiranyl and aziridinyl. Examples of non-aromatic heterocyclyl, which is 4-membered, include oxetanyl and azetidinyl. Examples of non-aromatic heterocyclyl, which is 5-membered, include oxathiolanyl, thiazolidinyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl .pyrazolinyl, tetrahydrofuryl, dihydrothiazolyl, tetrahydroisothiazolyl, dioxolanyl,dioxolyl, thiolanyl and the like. Examples of non-aromatic heterocyclyl, which is 6-membered, include dioxanyl, thianyl, piperidyl, piperazinyl, morpholinyl, morpholino, thiomorpholinyl, thiomorpholino, dihydropyridyl, tetrahydropyridyl, tetrahydropyranyl, dihydrooxazinyl, tetrahydropyrandinyl, hexahydropyrimidinyl, dioxazinyl, thiynyl, thiazinyl and the like. Examples of non-aromatic heterocyclyl, which is 7-membered, include hexahydroazepinyl, tetrahydrodiazepinyl and oxepanyl. The non-aromatic heterocyclyl, which is polycyclic, is preferably 8- to 20 membered and more preferably 8- to 10-membered. Examples include indolinyl, isoindolinyl, chromanyl, isochromanyl and the like.
[0031] The term "non-aromatic heterocycle" means a ring derived from "non-aromatic heterocyclyl" described above.
[0032] The term "protecting group for hydroxyl group" means a group replacing a hydrogen atom of a hydroxyl group, and a group which is deprotected by a general method, such as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), to generate hydroxyl group. Examples include aromatic carbocyclylalkyl optionally substituted by a group selected from Substituent Group B (e.g., benzyl, p-methoxyphenylbenzyl), alkylcarbonyl optionally substituted by a group selected from Substituent Group A (e.g., acetyl, pivaloyl, chloroacetyl), formyl, aromatic carbocyclylcarbonyl optionally substituted by a group selected from Substituent Group B (e.g., benzoyl), alkyloxycarbonyl optionally substituted by a group selected from Substituent Group A (e.g., methoxycarbonyl, isobutyloxycarbonyl, benzyloxycarbonyl, vinyloxycarbonyl), aromatic carbocyclyloxycarbonyl optionally substituted by a group selected from Substituent Group B (e.g., phenyloxycarbonyl), alkylsulfonyl optionally substituted by a group selected from Substituent Group A (e.g., mesyl), aromatic carbocyclylsulfonyl optionally substituted by a group selected from Substituent Group B (e.g., tosyl), trialkylsilyl (e.g., trimethylsilyl, triethylsilyl, t-butyldimethylsilyl), alkyloxyalkyl optionally substituted by a group selected from Substituent Group A (e.g., methoxymethyl, benzyloxymethyl, methoxyethoxymethyl), 2-(trimethylsilyl)ethoxymethyl, propenyl, phenacyl, tetrahydropyranyl, alkyl, and the like. Examples of "a protecting group for hydroxyl group except optionally substituted aromatic carbocyclylalkyl and optionally substituted aromatic heterocyclylalkyl" in RIa include alkylcarbonyl optionally substituted by a group selected from Substituent Group A, formyl, aromatic carbocyclylcarbonyl optionally substituted by a group selected from Substituent Group B, alkyloxycarbonyl optionally substituted by a group selected from Substituent Group A, aromatic carbocyclyloxycarbonyl optionally substituted by a group selected from Substituent Group B, alkylsulfonyl optionally substituted by a group selected from Substituent Group A, aromatic carbocyclylsulfonyl optionally substituted by a group selected from Substituent Group B, trialkylsilyl, alkyloxyalkyl optionally substituted by a group selected from Substituent Group A, 2-(trimethylsilyl)ethoxymethyl, propenyl, phenacyl, tetrahydropyranyl, alkyl and the like.
[00331 The term "protecting group for amino group" means a group replacing a hydrogen atom of an amino group, and a group which is deprotected by a general method, such as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), to generate amino group. Examples include trialkylsilyl (e.g., t-butyldimethylsilyl, 2,2,2-trichloroethoxycarbonyl), alkyloxycarbonyl optionally substituted by a group selected from Substituent Group A (e.g., t-butoxycarbonyl), aromatic carbocyclyloxycarbonyl optionally substituted by a group selected from Substituent Group B (e.g., benzyloxycarbonyl), aromatic carbocyclylalkyloxycarbonyl (e.g., 9-fluorenylmethyloxycarbonyl), aromatic carbocyclyloxycarbonyl, and the like. As the "protecting group for amino group" in R 2 , t-butyldimethylsilyl, t butoxycarbonyl or benzyloxycarbonyl is preferable.
?n
As the "protecting group for amino group" in R5 , Alloc or Fmoc is preferable.
[0034] The term "protecting group for carboxy group" means a group replacing a hydrogen atom of a carboxy group, and a group which is deprotected by a general method, such as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), to generate carboxy group. Examples include alkyl (e.g., methyl, ethyl, t-butyl), or aromatic carbocyclylalkyl optionally substituted by a group selected from Substituent Group B (e.g., benzyl).
[00351 The term "protecting group deprotectable by an acid" includes alkyl optionally substituted by a group selected from Substituent Group A and a ring wherein two R 4 may be taken together to form the ring. For example, when R 4 is alkyl, CH(OR4)(OR4) is dialkyl acetal (preferred is dimethylacetal), which is well known as a protecting group for aldehyde. Also, when two R 4 may be taken together to form a ring, -CH(OR4)(OR4) is cyclic acetal, which is well known as a protecting group for aldehyde. These protecting groups can be deprotected by an acid and converted to CHO.
[00361 The term "removable functional group" means a leaving group or a functional group which can be converted into a leaving group. Examples include optionally protected carboxy, optionally protected amino, optionally protected hydroxy, chlorine, bromine, iodine, or silyl-type functional group. Preferred is optionally protected carboxy, and more preferred is protected carboxy. The term "optionally protected carboxy" means carboxy or a group which can be deprotected according to a general method, such as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), to generate carboxy group. Preferred is alkyloxycarbonyl optionally substituted by a group selected from Substituent Group A (e.g., methyloxycarbonyl, ethyloxycarbonyl). The "optionally protected carboxy" may be deprotected to carboxy, which is then removed, or may be converted into "active ester", which is then removed. Examples of the "active ester" include those already reported, particularly, as an ester having high desorption ability, a group of the formula: -C(=)--R9 wherein R 9 is a group of the formula:
0 34N 0 Y S S N N N N 0 Y or 11 S~R Y Y wherein Y is each independently hydrogen or halogen; RI 0 is alkyl optionally substituted by a group selected from Substituent Group A or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group B; R11 is alkyl optionally substituted by a group selected from Substituent Group A or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group B. More preferred is a group of the following formula:
N y S 0 Y or S
Y Y wherein each symbol is as defined above.
[00371 "Silyl-type functional group" is any substance may be used as long as it can be removed by fluoride ion reagent. Examples include a group of the formula: -Si(RA4)3 wherein RA-4 is each independently alkyl optionally substituted by a group selected from Substituent Group A or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group B.
[0038] Example of a compound the formula (IV): R1 0 RA
oN RA 2 N N
RA 3 wherein "RAI is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is , CH 2 or CHRA; RA is a removable functional group; and the carbon atom to which RA is bound is optically active; provided that one of RA^, RA2 and RA3 is RA, the other two are hydrogen and X is 0 or CH 2, or RAl, R2 and RA3 are hydrogen and X is CHRA" includes compounds of the formulae shown below.
R O O RA RlO 0 RA RlO O RlO O 0 _ 0N 0 N R 0 0-''.R O O O RA O RA
H H H H H H H H (IVa) (lVb) (IVc) (IVd) RO 0 0 0
N N O N H H A HHA (IVe) RA (lVf) RA R- loR 1~ RO 0 RA R 0O0 RA RI. R 0 O 0 O O O RA O -RA Nt, N 0 N, N 'N, N RA N, N \R Nz Nz N N HH HH H H H H (IVg) (lVh) (lvi) (Vj) R O O O Rl~O O R O R1O 0 0 0N0 N0 RA 0 0 ' N 0 'N N N N'> 0 >N
HRA - ~ N' -RA _N! "RA H H H H H H (lVk) (IVI) RA (IVm) (IVn)
In particular, it is preferable that RAI is RA, further preferable is a compound of the formula (IVa), a compound of the formula (IVb), a compound of the formula (IVg), or a compound of the formula (IVh), and most preferable is a compound of formula (IVa).
[00391 In the following step to obtain a compound of the formula (IV) from a compound of the formula (III) or (VI), if the compound of the formula (IV) has (R)-configuration around the carbon atom attached with a dashed wedge line to hydrogen, the compound of the formula (III) or (VI) may have (R)- or (S)-configuration around the carbon atom to which RA is bonded, provided that desired steric configuration around the carbon atom to which RA is bonded should depend on the type of RA group, the position of RA or the condition of the intramolecular cyclization reaction. RI.-0 0 RI.-0 0 RAl z ' 0,R 10 0 RA RA2 0 RI.H00RA 0 N N NRA 30.' H__NH R8 NX 3 0 'N N-- _ A 5 NR H N RA 3 2 RA or RA RA 3 (l11) 2 (VI) RA (IV)
For example, a compound of the formula (IV) having (S)-configuration around the carbon atom attached with a dashed wedge line to hydrogen may be obtained by intramolecular cyclization reaction using a compound of the formula (III) or (VI) having (R)-configuration around the carbon atom to which RA is bonded. If so, a compound of the formula (IV) having (R)-configuration around the carbon atom attached with a dashed wedge line to hydrogen could be obtained by intramolecular cyclization reaction using a compound of the formula (III) or (VI) having (S) configuration around the carbon atom to which RA is bonded. Alternatively, a compound of the formula (IV) having (S)-configuration around the carbon atom attached with a dashed wedge line to hydrogen may be obtained by intramolecular cyclization reaction using a compound of the formula (III) or (VI) having (S)-configuration around the carbon atom to which RA is bonded. If so, a compound of the formula (IV) having (R)-configuration around the carbon atom attached with a dashed wedge line to hydrogen could be obtained by intramolecular cyclization reaction using a compound of the formula (III) or (VI) having() configuration around the carbon atom to which RA is bonded. Examples of such step include, but not limited to, the followings: RO1- 0 0 RA R1.. 0.0 RA S N 0 H X R8 3 0 N NH N,,,NNZX R H H (III') (IV )
R.0 0 Ri~o ~ RA 00 8 NHH X R RO 0 x\RA NR
2H H OO
R HH (1ilm) (IVm)
[0040] Preferred embodiments for each substituent and for the reaction conditions in each process are described below. The possible combinations of the following embodiments are preferable. A preferred embodiment for R1is benzyl or alkyl and alkyl is preferable. A preferred embodiment for1R2 is t-butyldimethylsilyl,t-butoxycarbonyl, or benzyloxycarbonyl, andt-butoxycarbonyl is preferable. A preferred embodiment for R3is alkyl or haloalkyl. A preferred embodiment for R4is hydrogen or alkyl. A preferred embodiment for Rais hydrogen, Alloc or Fmoc.
A preferred embodiment for R 6 is alkyl. A preferred embodiment for R, is NH2 or NHBoc. A preferred embodiment for R8 is -CHO or -CH(OR4)(OR4) wherein R 4 is hydrogen or alkyl. A preferred embodiment for RA is optionally protected carboxy, silyl-type functional group, and optionally protected carboxy is preferable. A preferred embodiment for R1 a is alkyl. A preferred embodiment for R, b is benzyl or alkyl. A preferred embodiment for Rc is benzyl or alkyl. A preferred embodiment for R3 a is hydrogen. A preferred embodiment for RB is alkyl. A preferred embodiment for Rc is alkyl. A preferred embodiment for RD is alkyloxy or dialkylamino. A preferred embodiment for Zl is chloro, bromo or iodo. A preferred embodiment for Z2 is hydrogen, halogen or alkyloxy.
[00411 General procedures of the process of the present invention are represented by the following schemes. As used herein, "solid wedge line" and "dashed wedge line" indicate absolute configuration. In a reaction of a compound with another compound, as described herein, these compounds may be a salt or a solvate thereof. Moreover, the reactions as described below may be conducted "in continuous steps" without isolation. Conducting "in continuous steps" comprises performing the next step without isolation of a compound obtained by the reaction in the preceding step. For example, two steps may be carried out in one-pot.
[0042] A compound of the formula (VIII) or (IX) can be used as a medicament in a form of a salt. Examples of such pharmaceutically acceptable salt of the compound of the formula (VIII) or (IX) include salts with alkaline metals (e.g., lithium, sodium, potassium), alkaline earth metals (e.g., calcium, barium), magnesium, transition metals (e.g., zinc, iron), ammonia, organic bases (e.g., trimethylamine, triethylamine. dicyclohexylamine, ethanolamine, diethanolamine, triethanolamine, meglumine, ethylenediamine, pyridine, picoline, quinoline) or amino acids, or salts with inorganic acids (e.g., hydrochloric acid, sulfuric acid, nitric acid, carbonic acid, hydrobromic acid, phosphoric acid, hydroiodic acid), or organic acids (e.g., formic acid, acetic acid, propionic acid, trifluoroacetic acid, citric acid, lactic acid, tartaric acid, oxalic acid, maleic acid, fumaric acid, mandelic acid, glutaric acid, malic acid, benzoic acid, phthalic acid, ascorbic acid, benzenesulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid), particularly, salts with hydrochloric acid, sulfuric acid, phosphoric acid, tartaric acid, methanesulfonic acid and the like. These salts can be formed in accordance with the conventional methods.
[00431 The meaning of each term is as follows. ABCN: 1,1'-azobis(cyclohexanecarbonitrile) acac: acetylacetonate AIBN: azobisisobutyronitrile Alloc: allyloxycarbonyl AZADO: 2-azaadamantan-N-oxyl Boc: tert-butoxycarbonyl COD: 1,5-cyclooctadiene CPME: cyclopentyl methyl ether DABCO: 1,4-diazabicyclo [2.2.2octane dba: dibenzylideneacetone DBDMH: 1,3-dibromo-5,5-dimethylhydantoin DBU: diazabicycloundecene DDDS: 4,4'-dichlorodiphenyl disulfide DMA: N,N-dimethylacetamide DME: dimethoxyethane DMF: N,N-dimethylformamide EDC: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Et 2 0: diethylether Fmoc: 9-fluorenylmethyloxycarbonyl HATU: 0-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate HF: hydrogen fluoride HOBt: 1-hydroxybenzotriazole MTBE: methyl tert-butyl ether n-Hex: n-hexyl NaH: sodium hydride NBS: N-bromosuccinimide NCS: N-chlorosuccinimide NIS: N-iodosuccinimide NMP: N-methyl-2-pyrrolidone TBABr: tetrabutylammonium bromide TBACl: tetrabutylammonium chloride TBAF: tetrabutylammonium fluoride TBAOAc: tetrabutylammonium acetate TFA: trifluoroacetic acid TEMPO: 2,2,6,6-tetramethylpiperidin-1-oxyl TEMPOL: 4-hydroxy-2,2.,6,6-tetramethylpiperidin-l-oxyl THF: tetrahydrofuran T3P: Propylphosphonic anhydride (cyclic trimer) V-70: 2,2'-azobis(4-methoxy-2,4-dimethylvaleronitrile) WSCD HCl: 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
[0044] Scheme 1
R0 RiaRla R a Rla Rla
01 Z1 "w01 OH -e. , OH 0 Step o Step 2 0 Step3 0 (X) (X1) (X2) (X3) wherein each symbol is as defined above.
[0045] Step 1 In this step, a compound of the formula (X) is reacted with a halogenating agent to give a compound of the formula (X). The compound of the formula (XI) can be obtained by reacting the compound of the formula (X) with a halogenating agent in the presence of a radical initiator. Examples of the radical initiator include AIBN, ABCN, V-70, triethylborane, diethylzinc and the like, preferably AIBN. Examples of the halogenating agent include NCS, NBS, NIS, chlorine, bromine, iodine, DBDMH and the like, preferably NBS. The reaction may be carried out in an amount of 1.0 to 3.0 molar equivalents, preferably 1.0 to 2.2 molar equivalents, based on the compound of the formula (X). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include ethyl acetate, acetonitrile, carbon tetrachloride, dichloromethane, THF, DMF, DMA and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes ethyl acetate, acetonitrile and carbon tetrachloride. The reaction temperature may be, but not limited to, about 0 to 100°C, preferably room temperature to 90°C. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[00461 Step 2 In this step, a compound of the formula (XI) is subjected to nucleophilic substitution with hydroxide ion to give a compound of the formula (X2). The compound of the formula (X2) can be obtained by reacting the compound of the formula (X1) with hydroxide ion in the presence of a base. Examples of the base include sodium carbonate, potassium carbonate, calcium carbonate, sodium hydroxide, potassium hydroxide, calcium hydroxide and the like, preferably calcium carbonate. The reaction may be carried out in an amount of 1.0 to 10 molar equivalents, preferably 2.0 to 5.0 molar equivalents, based on the compound of the formula (X1). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include acetonitrile, dioxane, water, dichloromethane, THF, DMF, DMA, DME and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes a mixture of acetonitrile and water and a mixture of dioxane and water. The reaction temperature may be, but not limited to, room temperature to 150°C, preferably room temperature to 100°C.
The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0047] Step 3 In this step, a compound of the formula (X2) is oxidized to give a compound of the formula (X3). The compound of the formula (X3) can be obtained by reacting the compound of the formula (X2) with a radical initiator and an oxidizing agent in the presence of a base. Examples of the base include sodium hydrogen carbonate, sodium carbonate, sodium hydroxide, potassium carbonate, calcium carbonate and the like, preferably sodium hydrogen carbonate. The reaction may be carried out in an amount of 1.0 to 2.0 molar equivalents, preferably 1.0 to 1.2 molar equivalents, based on the compound of the formula (X2). Examples of the radical initiator include TEMPO, AZADO, TEMPOL and the like, preferably TEMPO. Examples of the oxidizing agent include sodium chlorite, sodium hypochlorite, tert-butyloxychloride, NCS, metachloroperbenzoic acid and the like, preferably sodium hypochlorite. The reaction may be carried out in an amount of 2.0 to 5.0 molar equivalents, preferably 2.2 to 2.5 molar equivalents, based on the compound of the formula (X2). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include acetonitrile, water, dichloromethane, THF, DMF, DMA and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes a mixture of dichloromethane and water and a mixture of acetonitrile and water. The reaction temperature may be, but not limited to, about 0 to 100°C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[00481 Scheme 2 RB
R20 0, RD RD N NB Oi~ RB Rib O R1.O' O aR R(X5) 0 RE3 0 0 ~ O 1- H31.H Step 1 Step 2 Step3 O O (X4) (X6) (X7) (X8) wherein each symbol is as defined above.
[0049] Step 1 In this step, a compound of the formula (X4) is converted to an enamine by reacting with a compound of the formula (X5) or (X5) to give a compound of the
Qo formula (X6). The compound of the formula (X6) can be obtained by reacting the compound of the formula (X4) with the compound of the formula (X5) or (X5') in the presence of an additive agent. Examples of the compound of the formula (X5) or (X5) include DMF-dimethyl acetal, DMF-diethyl acetal, Brederick reagent, DMF-dimethyl sulfate adduct and the like, preferably DMF-dimethyl acetal. The reaction may be carried out in an amount of 1.0 to 10 molar equivalents, preferably 4.0 to 6.0 molar equivalents, based on the compound of the formula (X4). Examples of the additive agent include TBAOAc, TBACl, TBABr, DBU, diazabicyclononene, trimethylglycine, potassium acetate and the like, preferably TBAOAc. The reaction may be carried out in an amount of 0.5 to 3.0 molar equivalents, preferably 1.0 to 1.5 molar equivalents, based on the compound of the formula (X4). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include DMSO, dichloromethane, THF, DMF, DMA and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes DMSO and without solvent. The reaction temperature may be, but not limited to, about room temperature to 200°C, preferably 80°C to 150°C. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0050] Step 2 In this step, a compound of the formula (X6) is oxidatively cleaved to give a compound of the formula (X7). The compound of the formula (X7) can be obtained by reacting the compound of the formula (X6) with an oxidizing agent in the presence or absence of an acid. Examples of the oxidizing include sodium periodate, hydrogen peroxide, m chloroperoxybenzoic acid, potassium permanganate and the like, preferably sodium periodate. The reaction may be carried out in an amount of 1.0 to 3.0 molar equivalents, preferably 1.5 to 2.0 molar equivalents, based on the compound of the formula (X6). Examples of the acid include copper chloride (I) and the like. The solvent is not limited so long as it allows this step to proceed efficiently. Examples include acetonitrile, water, dichloromethane, THF, DMF, DMA and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes a mixture of acetonitrile and water. The reaction temperature may be, but not limited to, about 0 to 100C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0051] Step 3 In this step, a compound of the formula (X7) is oxidized to give a compound of the formula (X8). The compound of the formula (X8) can be obtained by reacting the compound of the formula (X7) in the same manner as in Step 3 of Scheme 1.
[0052] Scheme 3 Rc R0 N RiIo 0 Ri R 0c R c Z2 OR3 Ric RO RD (V1) 0 Z2 (V3) o 0 0,R Step 1 Step 2 o (X9) RC RC (V4) (V2) wherein each symbol is as defined above.
[0053] Step 1 In this step, a compound of the formula (X9) is reacted with a compound of the formula (VI) or (V') to give a compound of the formula (V2). The compound of the formula (V2) can be obtained by reacting the compound of the formula (X9) with the compound of the formula (VI) or (V1') in the presence of an additive agent. Examples of the compound of the formula (VI) or (V') include DMF-dimethyl acetal, DMF-diethyl acetal, Brederick reagent, DMF-dimethyl sulfate adduct and the like, preferably DMF-dimethyl acetal. The reaction may be carried out in an amount of 1.0 to 3.0 molar equivalents, preferably 1.5 to 2.5 molar equivalents, based on the compound of the formula (X9). Examples of the additive agent include formic acid, acetic acid, oxalic acid, citric acid, trifluoroacetic acid and the like, preferably acetic acid. The solvent is not limited so long as it allows this step to proceed efficiently. Examples include toluene, DMSO, dichloromethane, THF, DMF, DMA, cyclopentyl methyl ether and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes DMSO and DMA. The reaction temperature may be, but not limited to, about 0 to 100°C, preferably room temperature to 80°C. The reaction time may be, but not limited to, 0.5 to 48 hours, preferably 12 to 24 hours.
[00541 Step 2 In this step, a compound of the formula (V2) is reacted with a compound of the formula (V3) to give a compound of the formula (V4). The compound of the formula (V4) can be obtained by reacting the compound of the formula (V2) with the compound of the formula (V3) in the presence of a base and then subjecting the obtained compound to intramolecular cyclization in the presence ofan acid. Examples of the compound of the formula (V3) include dimethyl oxalate, diethyl oxalate, oxalyl chloride, monomethyl oxalate chloride, monoethyl oxalate chloride, preferably diethyl oxalate. The reaction may be carried out in an amount of 1.0 to 4.0 molar equivalents, preferably 2.0 to 3.0 molar equivalents, based on the compound of the formula (V2). Examples of the base include sodium methoxide, sodium ethoxide, sodium t butoxide, lithium diisopropylamide, lithium hexamethyldisilazide, sodium hexamethyldisilazide, potassium hexamethyldisilazide, DBU, DBN and the like, and preferably, sodium ethoxide. The solvent for the reaction with the compound of the formula (V3) is not limited so long as it allows this step to proceed efficiently. Examples include toluene, dichloromethane, THF, DMF, DMA and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solventincludes toluene. The reaction temperature for the reaction with the compound of the formula (V3) may be, but not limited to, about 0 to 100°C, preferably 0°C to room temperature. The reaction time for the reaction with the compound of the formula (V3) may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours. Examples of the acid include p-toluenesulfonic acid, methanesulfonic acid, trifluoroacetic acid, pyridinium p-toluenesulfonate and the like, preferably pyridinium p-toluenesulfonate The solvent for the intramolecular cyclization reaction is not limited so long as it allows this step to proceed efficiently. Examples include dichloromethane, THF, DMF, DMA, 1,3-dimethyl-2-imidazolidinone, N-methyl-2-pyrrolidone and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes DMA, DMF, 1,3-dimethyl-2-imidazolidinone and N-methyl-2-pyrrolidone. The reaction temperature for the intramolecular cyclization reaction may be, but not limited to, about 0 to 100°C, preferably room temperature to 70°C. The reaction time for the intramolecular cyclization reaction may be, but not limited to, 0.5 to 24 hours, preferably 0.5 to 4 hours.
[00551 Scheme 4 Ri. R1 R1 0 0 Step 1 O 0 Step 2 O 0 , R 0.3 - 0 ", R3 0 O0Rla
~NN2 (V5) (V6) (V7)
wherein each symbol is as defined above.
Step 1 In this step, a compound of the formula (V5) is reacted with ammonia to give a compound of the formula (V6). The compound of the formula (V6) can be obtained by reacting the compound of the formula (V5) with ammonia. Examples of ammonia include ammonia water, ammonium carbonate and ammonium acetate, preferably ammonium acetate. The reaction may be carried out in an amount of 1.0 to 10.0 molar equivalents, preferably 6 .0 to 10.0 molar equivalents, based on the compound of the formula (V5). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include water, methanol, ethanol, normal propanol, isopropanol, butanol, isobutanol, tert-butanol, tert amyl alcohol, ethyl acetate, acetonitrile, carbon tetrachloride, dichloromethane, THF, MTBE, CPME, DMF, DMA, NMP and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes water, normal propanol, isobutanol and NMP. The reaction temperature may be, but not limited to, generally about 0 to 100°C, preferably room temperature to 900 C. The reaction time may be, but not limited to, generally 0.5 to 24 hours, p referably1 to 12 hours.
Step 2 In this step, a compound of the formula (V6) is reacted with a hydroxylamine derivative to give a compound of the formula (V7). The compound of the formula (V7) can be obtained by reacting the compound of the formula (V6) with the hydroxylamine derivative in the presence of a base. Examples of the hydroxylamine derivative include hydroxylamine-O-sulf onic acid and 0-(2,4-dinitrophenyl)hydroxylamine, preferably hydroxylamine -0-sulfonic acid. The reaction may be carried out in an amount of 1.0 to 3.0 molar equivalents, preferably 2.0 to 2.5 molar equivalents, based on th e compound of the formula (V6). Examples of the base include sodium carbonate, potassium carbonate, calcium carbonate, cesium carbonate, sodium hydroxide, lithium hydroxide potassium hydroxide, calcium hydroxide, DBU, tetramethylguanidine, trip otassium phosphate, trisodium phosphate, and the like, preferably potassium carbonate, cesium carbonate, potassium hydroxide. The reaction may be carrie d out in an amount of 3.0 to 10 molar equivalents, preferably 5.0 to 8.0 molar equivalents, based on the compound of the formula (V6). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include water, methanol, ethanol, normal propanol, isopropanol, butanol, isobutanol, tert-butanol, tert-amyl alcohol, ethyl acetate, acetonitrile, carbon tetrachloride, dichloromethane, THF, MTBE, CPME, DMF, DMA, NMP and the like. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent may be water, tert-amyl alcohol, or the like. The reaction temperature may be, but not limited to, generally about 0 to 0 100 C, preferably room temperature to 400 C. The reaction time may be, but not limited to, generally 0.5 to 24 hours, p referably 1 to 12 hours.
[0056] Scheme 5
RA1 2 RA H2N R1- 0 0 X R8 RI.0 0 RAR
-R RA 3 (11) N,NRA20RA R H O NA RNH Step1 1N) O X R8 Step2 O NRA2 2 3 R (2lRA (1)IV H RA33 (la):R3=HR2 (Ib):R 2=H R6 3 RA N 'R5 R0 0 3A
X";RA (V 0 R3
RA 2N'R R WNH Step3 R N'R5 Step 4
(VI) RA' RA 2 O OHO00 0 Step 5 N Step 6 N N X N N Nt- NN~XN N.Ni X HN. 'HH H H N - P
N F or F (VII) F SF (VillI) (IX) wherein each symbol is as defined above.
[00571 Step 1 In this step, a compound of the formula (Ia) is reacted with a compound of the formula (II) to give a compound of the formula (III). The protecting group for carboxy group of the compound of the formula (I) can be removed to give the compound of the formula (Ia). The deprotection reaction can be carried out by a conventional method as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons). Thereafter, the obtained compound of the formula (Ia) is reacted with an amine of the formula (II) using a condensing agent in the presence or absence of a base to give a compound of the formula (III). Examples of the base include triethylamine and diisopropylethylamine. The solvent is not limited so long as it allows this step to proceed efficiently. Examples include dichloromethane, THF, DMF and DMA. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes dichloromethane. Examples of the condensing agent include dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, EDC, 4-(4,6 dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, HATU and WSCD- HCl. The condensing agent may be used in an amount of 1 to 5 molar equivalents, preferably 1 to 2 molar equivalents, based on the compound of the formula (Ia). The reaction temperature may be, but not limited to, about 0 to 100°C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours. The above step is carried out under conditions, which are selected appropriately so that RA should not be removed and not be reacted with another functional group.
[00581 Step 2 In this step, a compound of the formula (III)is subjected to intramolecular cyclization to give a compound of the formula (IV). For example, the compound of the formula (III) is subjected to intramolecular cyclization in the presence of an acid to give a compound of the formula (IV). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include acetonitrile, toluene and THF, which may be used alone or in combination. Preferred solvent includes acetonitrile. Examples of the acid include methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid, acetic acid and trifluoroacetic acid, which may be used alone or in combination. Preferred acid includes methanesulfonic acid. The acid may be used in an amount of 1 to 5 molar equivalents, preferably 1 to 3 molar equivalents, based on the compound of the formula (III). The reaction temperature may be, but not limited to, about 0 to 100°C, preferably room temperature to 80°C. The reaction time may be, but not limited to, 1 to 24 hours, preferably 1 to 12 hours. The above step is carried out under conditions, which are selected appropriately so that RA should not be removed and not be reacted with another functional group.
[00591 Step 3 In this step, a compound of the formula (Ib) is reacted with a compound of the formula (V) to give a compound of the formula (VI). The protecting group for amino group of the compound of the formula (I) can be removed to give the compound of the formula (Ib). The deprotection reaction can be carried out by a conventional method as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons). Thereafter, the obtained compound of the formula (Ib) is reacted with a compound of the formula (V) in the presence of an acid to give a compound of the formula (VI). Examples of the acid include Lewis acids such as boron trifluoride, tin tetrachloride, and zinc chloride, and bronsted acid such as methanesulfonic acid, p toluenesulfonic acid, camphorsulfonic acid, acetic acid and trifluoroacetic acid. Preferred acids include boron trifluoride and tin tetrachloride. The solvent is not limited so long as it allows this step to proceed efficiently. Examples include acetonitrile, toluene and THF, which may be used alone or in combination. Preferred solvent includes acetonitrile. The reaction temperature may be, but not limited to, about -80°C to room temperature, preferably -40 to 0°C. The reaction time may be, but not limited to, 0.1 to 24 hours, preferably 0.25 to 2 hours. The above step is carried out under conditions, which are selected appropriately so that RA should not be removed and not be reacted with another functional group.
[0060] Step 4 In this step, a compound of the formula (VI) is subjected to intramolecular cyclization to give a compound of the formula (IV). The compound of the formula (VI) may be subjected to intramolecular cyclization in the presence of a base, using a Pd catalyst if necessary, to give the compound represented by the formula (IV). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include acetonitrile, toluene and THF, which may be used alone or in combination. Preferred solvent include THF. Examples of the base include morpholine, piperidine and dimedone, which may be used alone or in combination. Preferred base includes morpholine. Examples of the Pd catalyst include tetrakistriphenylphosphine palladium. The reaction temperature may be, but not limited to, about 0 to 100°C, preferably at 20 to 50°C. The reaction time may be, but not limited to, 0.1 to 24 hours, preferably 1 to 4 hours. The above step is carried out under conditions, which are selected appropriately so that RA should not be removed and not be reacted with another functional group.
[00611 Step 5 In this step, RA group is removed from a compound of the formula (IV) to give a compound of the formula (VII).
[0062] Step 5-1 (RA = optionally protected carboxy) When RA is optionally protected carboxy, a protecting group for carboxy can be removed from the compound of the formula (IV) under a conventional condition for deprotection to give a corresponding carboxy acid. If the RA is carboxy, the carboxylic acid of the formula (IV) can be used as it is. The deprotection reaction can be carried out according to a conventional method as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons). The carboxylic acid is reacted using a photocatalyst and disulfide under light irradiation in the presence of a base to give a compound of the formula (VII). The solvent is not limited so long as it allows this step to proceed efficiently. Examples include methanol, ethanol, water, dichloromethane and dichloroethane, which may be used alone or in combination. Preferred solvent include a mixture of methanol and water.
Examples of the base include 2,6-lutidine, pyridine, DBU, diisopropylethylamine, triethylamine, N-methylimidazole, imidazole and DABCO. Preferred base includes 2,6-lutidine. Examples of the photocatalyst include acridinium salt. The acridinium salt is not limited so long as it allows the reaction under light irradiation to proceed efficiently. Preferred examples include 9-mesityl 10-alkyl acridinium salt and 9 mesityl 10-aromatic carbocyclylacridinium salt. Preferred examples include 9 mesityl-2,7-dimethyl 10-methyl acridinium salt and 9-mesityl 10-methylacridinium salt. Disulfide is a compound having a disulfide group as a functional group. Examples include di(aromatic carbocyclyl) disulfide. Preferred disulfides include diphenyl disulfide and 4,4'-dichlorodiphenyl disulfide. Examples of the light include blue LED. The reaction temperature may be, but not limited to, about 0 to 50°C, preferably room temperature. The reaction time may be, but not limited to, 0.5 to 48 hours, preferably 1 to 24 hours.
[00631 Step 5-2 (RA = optionally protected carboxy) The carboxylic acid can be obtained in the same manner as in Step 5-1. The carboxylic acid may be reacted with a N-hydroxy compound etc. using a condensing agent in the presence or absence of a base to give an active ester. Examples of the base include triethylamine, diisopropylethylamine and DABCO. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include dichloromethane, THF, DMF and DMA. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes dichloromethane. Examples of the condensing agent include dicyclohexylcarbodiimide, carbonyldiimidazole, dicyclohexylcarbodiimide-N-hydroxybenzotriazole, EDC, WSCD•HCl, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, HATU and T3P, which may be used in an amount of 1 to 5 molar equivalents, preferably 1 to 2 molar equivalents, based on the compound (IV). The reaction temperature may be, but not limited to, about 0 to 100°C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[00641 The obtained active ester is decarboxylated using a metal catalyst, a ligand and a reducing agent to give a compound of the formula (VII). Examples of the metal catalyst include a nickel catalyst, a palladium catalyst, a copper catalyst, a cobalt catalyst and an iron catalyst such as NiC 2 , NiBr2, Ni 2 ,
Ni(COD) 2 , Ni(acac)2, Pd2 (dba): 3, PdC 2 , Pd(OAc) 2 , CuCl, CuBr, Cul, CuCl2, CuBr2, CuI2, Cu(OAc), Cu(OAc)2, Co(acac)2, Co(acac)3, CoCl2, CoBr2, CoI2, Fe(OAc)2, Fe(acac)2, Fe(acac)3, FeCl2, FeBr2. FeI2, and the like. Preferred metal catalyst include NiCl 2 -5H 2 0. Examples of the ligand include PPh3, Xantphos and 2,2'-bipyridine derivatives. The 2,2'-bipyridine derivative is not limited so long as it allows to work as a bipyridine ligand. Examples include 4,4'-dimethyl-[2,2']bipyridine, 4,4'-diethyl
[2,2']bipyridine, 4,4'-dinonyl-[2,2']bipyridine, 4,4'-dicyano-2,2'-bipyridine, 2,2' bipyridine-4,4'-dicarboxylic acid, dimethyl 2,2'-bipyridine-4,4'-dicarboxylate, 2,2' bipyridine-4,4'-dicarboxamide, 4,4'-bis(hydroxymethyl)-2,2'-bipyridine, 4,4' bis(bromomethyl)-2,2'-bipyridine, tetraethyl 2,2'-bipyridine-4,4' diylbis(methylene)diphosphonate, (E/Z)-4,4'-distyrvl-2,2'-bipyridine, 4,4'-dimethoxy 2,2'-bipyridine, diisobutyl 2,2'-bipyridine-4,4'-dicarboxylate, 4,4'-di-tert-butyl-2,2' bipyridine, and the like. Preferred ligand includes 4,4'-di-tert-butyl-2,2'-bipyridine. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, isopropyl alcohol and dichloromethane. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes a mixture of DMF, THF and isopropyl alcohol. Examples of the reducing agent include zinc, manganese, phenylsilane, triethylsilane, chlorosilane and mixtures thereof. Preferred reducing agent includes a mixture of zinc and phenylsilane The reaction temperature may be, but not limited to, about 0 to 100°C, preferably room temperature to 80°C. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0065] The obtained active ester is decarboxylated using thiol or other reducing agent in the presence or absence of a radical initiator to give a compound of the formula (VII). Thiol is a compound having a hydrogenated sulfur at the terminal. Examples include alkylthiol optionally substituted by a group selected from Substituent Group C and aromatic carbocyclylthiol optionally substituted by a group selected from Substituent Group D. Preferred thiol includes t-nonanethiol. Examples of the other reducing agent include tin hydride and tris (trimethylsilyl)silane. Examples of the radical initiator include AIBN, ABCN, V-70, triethylborane and diethylzinc. Preferred radical initiator includes AIBN. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, isopropyl alcohol and dichloromethane. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvent includes DMA. The reaction temperature may be, but not limited to, about 0 to 1000 C, preferably room temperature to 80°C. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0066] Step 5-3 (RA = silyl-type functional group) The compound of the formula (IV) is reacted with a fluoride ion reagent to give the compound of the formula (VII). Examples of the fluoride ion reagent include TBAF, HF - pyridine, HF triethylamine. Preferred fluoride ion reagent includes TBAF. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, dichloromethane and ethyl acetate. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvents include THF and dichloromethane. The reaction temperature may be, but not limited to, about 0 to 100°C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0067] Step 5-4(1) (RA = optionally protected amino) The protecting group for amino group is removed from a compound of the formula (IV) under a conventional condition for deprotection. The obtained amine is diazotizated and then reduced to give a compound of the formula (VII). The deprotection reaction can be carried out by a conventional method as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons). Examples of the reducing agent include hypophosphorous acid. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, dichloromethane and ethyl acetate. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvents include THF and dichloromethane. The reaction temperature may be, but not limited to, about 0 to 100C, preferably room temperature to 80°C. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[00681 Step 5-4(2) (RA = optionally protected amino) The protecting group for amino group is removed from a compound of the formula (IV) under a conventional condition for deprotection. The obtained primary amine is converted into isonitrile and then reduced using a reducing agent in the presence or absence of radical initiator to give a compound of the formula (VII). The deprotection reaction can be carried out by a conventional method as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons). Examples of the reducing agent include tin hydride, tris(trimethylsilyl) silane and thiol. Examples of the radical initiator include AIBN, ABCN, V-70, triethylborane and diethylzinc. Preferred radical initiator includes AIBN. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, dichloromethane and ethyl acetate. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvents include THF and dichloromethane.
The reaction temperature may be, but not limited to, about 0 to 100°C, preferably room temperature to 80°C. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0069] Step 5-5 (RA = chlorine, bromine or iodine) The compound of the formula (IV) is reduced to remove RA group to give a compound of the formula (VII). Examples of the reduction condition include Pd-C/H 2 , NaBHLiBH 4 and LAH. Preferred reduction condition includes Pd-C/H 2
. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, dichloromethane and ethyl acetate. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvents include THF and dichloromethane. The reaction temperature may be, but not limited to, about 0 to 100°C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[00710) Step 5-6 (RA = optionally protected hydroxy) The protecting group for hydroxy group is removed from a compound of the formula (IV) under a conventional condition. The hydroxy group of the obtained compound is converted into pseudohalide and then reductively removed to give a compound of the formula (VII). The deprotection reaction can be carried out by a conventional method as described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons) and the like. Examples of the pseudohalide include mesylate, tosylate and triflate. Preferred pseudohalide includes triflate. The solvent is not limited so long as it allows the step to proceed efficiently. Examples include DMF, DMA, THF, dichloromethane and ethyl acetate. The reaction can be carried out in a single solvent, in a mixed solvent, or without solvent. Preferred solvents include THF and dichloromethane. The reaction temperature may be, but not limited to, about 0 to 100C, preferably 0°C to room temperature. The reaction time may be, but not limited to, 0.5 to 24 hours, preferably 1 to 12 hours.
[0071] Step 6 The compound of the formula (VIII) or (IX) can be obtained according to the method described in any one of Patent Documents 19 to 21.
[00721 As used herein, "diastereomer ratio" refers to the ratio of the HPLC area percentage or NMR peak intensity between the two stereoisomers as shown below.
R!0 0 R1 0 0 0l 0 1v> __ N
' AN 'N X ~ N X N H
' H a b wherein each symbol is as defined above.
[0073] The present invention will be explained in more detail below by way of Examples, but the present invention is not limited by them.
[00741 The NMR analysis was carried out at 400 MHz, using DMSO-d or CDC. RT represents a retention time at LC/MS: liquid chromatography/mass spectrometry, and was measured under the following conditions.
(Measurement Condition)
[1] Column: ACQUITY UPLC (Registered trademark) BEH C18 (1. 7 pm i.d.2.1x50mm) (Waters) Flow rate: 0.8 mL/min UV detection wavelength: 254nm Mobile phase: [A]: 0.1% formic acid in water, [B]: 0.1% formic acid in acetonitrile Gradient: a linear gradient of 5% to 100% solvent [B] over 3.5 minutes, and then 100% solvent [B] kept for 0.5 minutes.
[0075] Measurement of X-ray powder diffraction pattern The powder X-ray diffraction measurement of the crystal obtained in each Example was carried out according to the general test method described in the Japanese Pharmacopoeia. The measurement conditions are as follows.
[0076] Apparatus: MinFlex 600 RINT-TTRIII (Rigaku Corporation) Detector: high-speed one-dimensional detector (D/TecUltra 2) with variable knife edge Detection mode: reflection Light source: Cu bulb Operating Wavelength: CuKa rays Tube current: 10 mA, or 15 mA Tube voltage: 30 Kv, or 40 Kv Sample plate: aluminum or glass X-ray incidence angle (6): 3-40°, sampling width: 0.01°, or X-ray incident angle (0): 4-40°, sampling width: 0.02°
All
Generally, the diffraction angles (20) in X-ray powder diffraction may contain errors within the range of ±0.2, and thus, the values of the diffraction angles should be understood to include values within the range of±0.2°. Therefore, the present invention encompasses crystals having peak diffraction angles that match within an error of ±0.2°, as well as the crystals having peak diffraction angles that completely match in the X-ray powder diffraction. Also, the data, especially the X-ray intensity, may vary significantly depending on the conditions of the X-ray diffraction measurement, such as loading method of the crystals into the X-ray diffraction apparatus and particle size of the crystals. Thus, the identity of the crystal form of the compound is not denied even if the data do not match in the relative intensity of the peak.
[00771 Example I C0 2H CO 2H CO 2 Me BocsN Boc. N OMe H 2N OMe H O Step H OMe Step 2 OMe 1 2 ~ 3~
Bn O n-Hex 0 n-Hex,.0 O n-Hex, 0 0
0 Step 3 O Step 4 0____ Ste 5 Hc . tN._ 0 .. NHO~ Step HO 4 5 6 7
n-HexNO 0 CO 2 Me n-Hex 0 0 CO 2Me 410 0 N 3We~ Step O NH Step7 O NHBoc OMe H 8 9 n-Hex, 0 0 C0 2 H n-Hex, 0 O
Step8 Step 9 H H 10 11
Step 1 To a suspension of NaH (3.96 g, 99 mmol) in DMF (36 mL) was added dropwise a solution of Boc-L-serine (9.27 g, 45 mmol) in DMF (45 mL) for 30 minutes with ice cooling under nitrogen atmosphere, and then added dropwise bromoacetaldehyde dimethylacetal (10.6 mL, 90 mmol) for 10 minutes. The mixture was warmed up to room temperature over 3 hours and was stirred for 5 hours. The mixture was poured into water (90 g) and concentrated. The aqueous layer was washed with Et2 0 and the pH was adjusted to 3.3 by adding hydrochloric acid. The aqueous layer was extracted with ethyl acetate (100 mL). The aqueous layer was extracted again with ethyl acetate (100 mL). The organic layers were combined and dried over sodium sulfate and concentrated under reduced pressure to obtain crude Compound 2 (9.52 g). 1H-NMR (CDCl3): 5.54-5.52 (br m, IH), 4.50 (t, J = 5.1 Hz, 1H), 4.44-4.42 (br m, 1H), 4.01-3.99 (br m, 1H), 3.74 (dd, J = 9.7, 4.1 Hz, 1H), 3.55 (d, J = 5.1 Hz, 2H), 3.39 (s, 6H), 1.47 (s, 9H).
Step 2 To a solution of the crude Compound 2 (9.52 g) in methanol (33 mL) was added methanesulfonic acid (6.32 mL, 97 mmol) at 0°C under nitrogen atmosphere, and the mixture was stirred at room temperature for 18 hours. The solvent was removed from the mixture under reduced pressure, and the obtained residue was added to an aqueous solution of potassium carbonate at 0°C. The mixture was extracted five times with chloroform (50 mL). The organic layers were combined and washed with brine (20 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain Compound 3 (3.76g, 40% in 2 steps). 1H-NMR (CDC3): 4.48 (t, J 5.2 Hz, 1H), 3.80-3.70 (in, 5H), 3.65 (t, J = 4.7 Hz, 1H), 3.52 (d, J = 5.1 Hz, 2H), 3.39 (s, 6H).
Step 3 To a solution of Compound 4 (3.00 g, 11.5 mmol) in dichloromethane (12 mL) was added TFA (8.88 mL, 13.1 mmol) under nitrogen atmosphere, and the mixture was stirred at room temperature for 18 hours. The mixture was concentrated under reduced pressure, and the obtained solid was treated with a mixed solution of diisopropyl ether and hexane (1:1) and filtered to obtain a deprotected product (1.98 g). To a solution of the obtained compound (1.98 g, 11.6 mmol) in DMA (40 mL) were added 1-iodohexane (5.15 mL, 35.0 mmol) and DBU (5.26 mL, 35.0 mmol), and the mixture was stirred at room temperature for 18 hours. To the mixture was added 1M aqueous hydrochloric acid, and the mixture was extracted theree times with ethyl acetate. The organic layer was washed with water and brine, dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (hexane-ethyl acetate) to obtain Compound 5 (2.42 g, 82%). LC/MS (ESI):m/z = 255 [M+H]•, RT=1.97 min
Step 4 Compound 6 was obtained in the same manner as described in W02016/175224.
Step 5 To a solution of Compound 6 (3.00 g, 8.14 mmol) in ethanol (7.86 mL) was added 2M aqueous sodium hydroxide (17.8 mL, 35.6 mmol) under nitrogen atmosphere, and the mixture was stirred at 60°C for 6 hours. To the mixture was added 2M aqueous hydrochloric acid (18 mL), and then added water. The precipitated solid was filtered and washed with water to obtain Compound 7 (2.75 g, %). LC/MS (ESI):m/z = 354 [M+H]•, RT=1.24 min
Step 6
To a solution of Compound 3 (494 mg, 2.03 mmol) and Compound 7 (532 mg, 1.50 mmol) in DMF ( I mL) were added HOBt (263 mg, 1.95 mmol) and WSCD -HCl (374 mg, 1.95 mmol) at 0°C under nitrogen atmosphere, and the mixture was stirred at 0°C for 2 hours and then stirred at room temperature for 1 hour. To the mixture was added water (20 mL), and the mixture was extracted twice with ethyl acetate (30 mL). The organic layer was washed with a saturated aqueous sodium bicarbonate (20 mL) and brine (20 mL). The organic layers were combined and dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 8 (777.0 mg, 95%). 1 H-NMR (CDCl)6: 8.54 (s, 1H), 8.09 (s, 1H), 7.34 (d, J = 7.9 Hz, 1H), 6.38 (d, J = 7.8 Hz, 1H), 4.77-4.74 (in, 1H), 4.44 (t, J = 5.1 Hz, 1H), 4.31-4.18 (in, 2H), 4.04 (dd, J = 9.7, 3.5 Hz, 1H), 3.81-3.74 (m, 4H), 3.51 (d, J = 5.1 Hz, 2H), 3.36 (d, J = 2.1 Hz, 6H), 1.75-1.60 (m, 2H), 1.48 (s, 9H), 1.42-1.25 (in, 6H), 0.88 (t, J = 6.8 Hz, 3H).
Step 7 To a solution of Compound 8 (114 mg, 0.21 mmol) in acetonitrile (2.3 mL) were added water (0.46 mL) and methanesulfonic acid (0.041 mL, 0.63 mmol) under nitrogen atmosphere, and the mixture was stirred at 600 C for 3 hours. To the mixture was added a saturated aqueous sodium bicarbonate (5 mL), and the mixture was extracted theree times with chloroform (10 mL). The organic layers were combined and washed with brine (5 mL), dried over anhydrous sodium sulfate and concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 9 (58.5 mg, %). ' H-NMR (CDCls)5: 7.36 (d, J = 7.7 Hz, 1H), 6.25 (d, J = 7.7 Hz, 1H), 5.55 (d, J = 13.4 Hz, 1H), 5.00-4.95 (in, 2H), 4.50 (d, J = 11.9 Hz, 1H), 4.28-4.23 (m, 1H), 4.14 (dd, J = 11.4, 4.7 Hz, 1H), 3.99-3.84 (m, 2H), 3.78 (s, 3H), 3.25 (t, J = 10.8 Hz, 1H), 1.78-1.70 (in, 2H), 1.60 (s, 9H), 1.40-1.25 (m, 6H), 0.87 (t, J = 6.9 Hz, 3H).
Step 8 To a solution of Compound 9 (100 mg, 0.26 mmol) in methanol (1.0 mL) and THF (0.5 mL) was added 2M aqueous sodium hydroxide (0.26 mL, 0.53 mmol) at 0°C under nitrogen atmosphere, and the mixture was warmed up to room temperature over 4 hours with stirring. To the mixture was added IN aqueous hydrochloric acid (0.55 mL), and the mixture was extracted theree times with chloroform (10 mL). The organic layers were combined and washed with brine (10 mL), dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure to obtain Compound 10 (85.3 mg, 89%). 'H-NMR (DMSO-D)6: 7.71 (d, J = 7.7 Hz, 1H), 7.35 (d, J = 12.8 Hz, 1H), 6.21 (d, J 7.7 Hz, 1H), 4.90-4.83 (in, 2H), 4.34 (d, J = 11.9 Hz, 1H), 4.07 (dd, J = 11.3, 4.6 Hz, 1H), 3.95 (dt, J = 21.9, 7.8 Hz, 2H), 3.71 (dd, J = 12.0, 3.8 Hz, 1H), 3.17 (t, J = 10.9 Hz, 1H), 1.69-1.58 (m, 2H), 1.39-1.23 (in, 6H), 0.86 (t, J = 6.8 Hz, 3H).
Step 9 To a mixture of Compound 10 (37 mg, 0.10 mmol), DDDS (2.87 mg, 10 pmol) and 9-mesityl-2,7-dimethyl 10-methyl acridinium salt (0.88 mg, 2.0 pmol) were added
9i methanol (1.8 mL) and water (45pL, 2.5 mmol) under nitrogen atmosphere. After degassing with nitrogen bubbling for 15 minutes, 2,6-lutidine (2.3 pL, 20 pmol) was added. The mixture was stirred at room temperature under blue LED illumination for 14 hours. The mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 11 (29.4mg, 92%).
[00781 Example 2 0 n-Hex. 0 0 C0 2 H n-Hex 0 0N n-Hex 0 0
01"0 HNN I,, Step 1 N Step 2
10 H 12 11
Step 1 To a solution of Compound 10 (183 mg, 0.50 mmol) and N-hydroxyphthalimide (163 mg, 1.00 mmol) in dichloromethane (1.8 mL) was added WSCD-HC1 (288 mg, 1.50 mmol) at 0°C under nitrogen atmosphere, and the mixture was stirred at room temperature for 1 hour. To the mixture was added water (10 mL), and the mixture was extracted twice with ethyl acetate (20 mL). The organic layer was washed with brine (10 mL), dried over anhydrous sodium sulfate and the solvent was removed under reduced pressure. The obtained residue was purified by silica gel column chromatography (ethyl acetate) to obtain Compound 12 (203 mg, 80%). 1H-NMR (CDCls)6: 7.90-7.79 (in, 4H), 7.35 (d, J = 7.7 Hz, 1H), 6.20 (d, J = 7.7 Hz, H), 5.81 (d, J = 13.3 Hz, 1H), 5.41 (d, J = 3.5 Hz, 1H), 5.07-5.01 (in, 1H), 4.74 (d, J 12.2 Hz, 1H), 4.28-4.17 (in, 3H), 3.90 (dd, J = 16.1, 7.1 Hz, 1H), 3.40 (t, J = 10.8 Hz, 1H), 1.80-1.68 (in, 2H), 1.40-1.24 (in, 6H), 0.83 (t, J = 6.9 Hz, 3H).
Step 2 To a mixture of Compound 12 (51 mg, 0.10 mmol) and zinc powder (3.27 mg, 50 pmol) were added THF (0.5 mL) and 2-propanol (pL) under nitrogen atmosphere. After degassing with nitrogen bubbling for 15 minutes, a solution of nickel chloride hexahydrate (2.4 mg, 10 pmol) and 4,4'-di-tert-butyl-2,2'-bipyridine (5.37 mg, 20 pmol) in DMF (0.1 mL) was added. To the mixture was added phenylsilane (37 pL, 0.3 mmol), and the mixture was stirred at 60°C for 2 hours. The mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 11 (15mg, 48%).
[0079] Example 3
S Bn' 0 O C0 2H BnS Bn 00
O N OO-N 5 N H RN 'N~ H 13 H 14 15
To a solution of Compound 13 (37.1 mg, 1.00 mmol), which was synthesized in the same manner as described in Step 1 to Step 8 of Example 1, and 3-hydroxy-4 methylthiazol-2(3H)-thione (22.1 mg, 1.50 mmol) in N-methyl pyrrolidone (0.9 mL) were added DABCO (44.9 mg, 4.00 mmol) and T3P (255 mg, 4.00 mmol) at room temperature under nitrogen atmosphere, and the mixture was stirred at room temperature for 2 hours to obtain a solution of Compound 14. To the mixture was added t-nonanethiol (0.9 mL, 74 mmol) under nitrogen atmosphere, and the mixture was stirred at 55°C for 2 hours. The mixture was concentrated under reduced pressure. The obtained residue was purified by silica gel column chromatography (chloroform-methanol) to obtain Compound 15 (27 mg, 83%). 1 H-NMR (DMSO): 2.80-3.00(m, 1H), 3.10-3.18(m, 1H), 3.38-3.50(m, 1H), 3.98-4.08(m, 2H), 4.10-4.20(m, 1H), 4.76-4.84(m, 1H), 5.04-5.14(m, 2H), 6.22(m, J=71.6Hz, 1H1), 7.27-7.40(m, 4H4), 7.56-7.60(m, 2H), 7.70(d, J=7.6Hz, 1H).
[00801 Example 4 Bn O O OH O BnN0 O O N 0 N
0: .NA5 O Step 1 F Step 2 H F F 15 F F 16 (VIlla)
Step 1 Compound 15 (1100 g, 3360 mmol) and 7,8-difluoro-6,11 dihydrodibenzothiepine-11-ol (977 g, 3697 mmol) were suspended in 50wt% T3P in ethyl acetate (3208 g, 5041 mmol) and ethyl acetate (1.1 L). To the mixture was added methanesulfonic acid (436 mL, 6721 mmol) at room temperature and the mixture was stirred at 70°C for 5.5 hours. To the mixture was added water with ice cooling, and the mixture was stirred at room temperature for 1 hour. THF was added, and the mixture was extracted with ethyl acetate. The organic layer was washed with water and 8% aqueous sodium bicarbonate, dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The obtained residue was dissolved in THF (5.5 L), and potassium carbonate (790 g, 5713 mmol) was added. The mixture was warmed up to 50°C, and benzyl bromide (240 mL, 2016
All mmol) was added dropwise, and the mixture was stirred at 60°C for 8.5 hours. To the mixture was added dropwise 2mol/L aqueous hydrochloric acid with ice cooling, and the mixture was stirred at room temperature for 10 minutes and extracted with ethyl acetate. The organic layer was washed with water and 8% aqueous sodium bicarbonate and dried over anhydrous magnesium sulfate. An activated carbon (Norit SX-2, 240 g) was added, and the mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure To the obtained residue was added ethyl acetate and hexane, and the presipitated solid was filtered to obtain Compound 16 (1019 g, 1776 mmol, 53%). 1 H-NMR (CDCl 3)6: 2.88 (1H, t, J = 11.2 Hz), 3.28-3.39 (2H, m), 3.72 (1H, d, J = 12.6 Hz), 3.86 (1H, d, J = 9.6 Hz), 4.03 (1H, d, J = 13.9 Hz), 4.45 (1H, d, J = 8.6 Hz), 4.67 (1H, d, J = 13.1 Hz), 5.19-5.26 (2H, m), 5.45 (H, d, J = 10.9 Hz), 5.63 (H, d, J = 10.9 Hz), 5.77 (1H, d, J = 7.6 Hz), 6.40 (1H, d, J = 7.8 Hz), 6.68 (1H, t, J = 6.9 Hz), 6.94 7.01 (2H, in), 7.03-7.12 (3H, in), 7.29-7.38 (3H, in), 7.61 (2H, d, J = 7.1 Hz).
Step 2 To a solution of Compound 16 (1200 g, 2092 mmol) in DMA (3.6 L) was added lithium chloride (443g, 10.5 mol) at room temperature, and the mixture was stirred at °C for 3 hours. To the mixture were added acetone (1.2L), 0.5mol/L aqueous hydrochloric acid (6.0 L) and water (2.4 L) with ice cooling, and the mixture was stirred for 1 hour. The presipitated solid was filtered. The obtained solid was dissolved in chloroform, and isopropyl ether was added to presipitate solid, which was filtered to obtain Compound (VIlla) (950 g, 1965 mmol, 94%). 1 H-NMR (CDClIs)6: 2.99 (1H, dt, J = 17.5, 6.8 Hz), 3.47 (1H, td, J = 11.9, 2.5 Hz), 3.60 (H, t, J = 10.6 Hz), 3.81 (H, dd, J = 11.9, 3.3 Hz), 3.96 (1H, dd, J = 11.0, 2.9 Hz), 4.07 (1H, d, J = 13.8 Hz), 4.58 (1H, dd, J = 10.0, 2.9 Hz), 4.67 (1H dd, J = 13.5, 1.9 Hz), 5.26-5.30 (2H, m), 5.75 (iH, d, J = 7.8 Hz), 6.69 (1H, d, J = 7.7 Hz), 6.83-6.87 (1H, in), 6.99-7.04 (2H, in), 7.07-7.15 (3H, in).
[0081] Example 5 n-Hex. 0 O OH 0 n-Hex, 0 O O N NY O N > ' N'N IO NN SN'N O Step 1 Step 2 H F F 11 F S F S 17 (Villa)
Step 1 To Compound 11 (12.0 g, 24.3 mmol) were added 7,8-difluoro-6,11 dihydrodibenzothiepin-11-ol (8.0 g, 30.3 mmol), ethyl acetate (48.7 g) and cyclohexane (14.1 g), and the mixture was stirred at 25°C. 50 (w/w)% T3P in ethyl acetate (20.91 g,32.9 mmol) was added, followed by addition of methanesulfonic acid (3.5 g, 36.4 mmol). The mixture was heated to 60°C and stirred for 24 hours. After cooling to
0 C, THF (32.0 g) and water (24.0 g) were added, and then 24% aqueous sodium hydroxide (30.8 g) was slowly added. The mixture was allowed to stnad, and the organic layer and the aqueous layer were separated. The organic layer was washed twicewith7% aqueous sodium chloride (60.0 g). To the obtaned solution were added a mixture of cyclohexane (9.3 g), ethyl acetate (32.1 g) and methanesulfonic acid (2.80 g,29.1 mmol). The mixture was stirred at 25°C for 2 hours, and the resulting white precipitate was filtered. The obtained solid was washed with ethyl acetate (43.3 g) and dried to obtain mesylate of compound 17 (13.65 g, 84.6%). 1 H-NMR (DMSO-d 6)6: 0.90 (3H, t, J = 6.0 Hz), 1.29-1.36 (4H, in), 1.39-1.49 (2H, m), 1.67-1.79 (2H, in), 2.38 (3H, s), 2.94 (1H, br s), 3.30 (1H, td, J = 11.6, 2.4 Hz), 3.51 (1H, t, J = 10.4 Hz), 3.66 (1H, dd, J = 11.2, 2.8 Hz), 3.92-4.01 (2H, in), 4.07 (1H, d, J 14.3 Hz), 4.20 (1H, s), 4.42-4.52 (1H, in), 5.43 (1H, dd, J = 14.4, 2.1 Hz), 5.79-5.83 (2H, in), 6.81 (1H, td, J = 7.6, 1.2 Hz), 6.96 (1H, dd, J = 7.8, 1.0 Hz), 7.09 (1H, J = 8.0, 1.6 Hz), 7.12-7.18 (1H, in), 7.32 (1H, d, J = 7.7 Hz), 7.37-7.49 (2H, m)
Step 2 To Compound 17 (15.0 g, 22.6 mmol) were added N-methylpyrrolidone (52.4 g), and the mixture was stirred. Lithium chloride (8.6 g, 203.3 mmol) was added, and the mixture was heated to 75°C. The mixture was stirred at 750 C for 20 hours and then cooled to 40°C. Acetonitrile (20.0 g) was added, followed by addition of water (11.6 g). After cooling the mixture to 30°C and stirring for 30 minutes, water (142.5 g) was slowly added. After stirring at 30°C for 1.5 hours, the resulting white precipitate was filtered. The obtained solid was washed with 2-propanol (60.1 g) and dried to obtain Compound (VIlla) (9.91 g, 90.7%).
[0082] Example 6 0 OH 0 O MeO 0 0 0
N1 ~~'N O ~
(Villa) F(IXa)
To a suspention of Compound (VIlla) (1.00 g, 2.07 mmol) in DMA (5 mL) were added chloromethyl methyl carbonate (0.483 g, 3.10 mmol), potassium carbonate (0.572 g, 4.14 mmol) and potassium iodide (0.343 g, 2.07 mmol), and the mixture was stirred at 50°C for 6 hours. To the mixture was added DMA (1 mL), and the mixture was stirred for 6 hours. The mixture was cooled to room temperature, DMA (6 mL) was added, and the mixture was stirred at 50°C for 5 minutes. The mixture was filtered. To the obtained filtrate were added dropwise 1mol/L aqueous hydrochloric acid (10 mL) and water (4 mL) with ice cooling, and the mixture was stirred for 1 hour. The presipitated solid was filtered and dried under reduced pressure at 600 C
.17 for 3 hours to obtain Compound (IXa) (1.10g, 1.93 mmol, 93%). 1H-NMR (DMSO-D6) 6: 2.91-2.98 (H, in), 3.24-3.31 (1H, in), 3.44 (1H, t, J = 10.4 Hz), 3.69 (1H, dd, J = 11.5, 2.8 Hz), 3.73 (3H, s), 4.00 (1H, dd, J = 10.8, 2.9 Hz), 4.06 (1H, d, J = 14.3 Hz), 4.40 (H, d, J = 11.8 Hz), 4.45 (1H, dd, J = 9.9, 2.9 Hz), 5.42 (1H, dd, J = 14.4, 1.8 Hz), 5.67 (1H, d, J = 6.5 Hz), 5.72-5.75 (3H, in), 6.83-6.87 (1H, in), 7.01 (iH, d, J = 6.9 Hz), 7.09 (1H, dd, J = 8.0, 1.1 Hz), 7.14-7.18 (1H, in), 7.23 (1H, d, J 7.8 Hz), 7.37-7.44 (2H, in).
[00831 Example 7
n-Hex 0 O C0 2H n-Hex' 0 O C0 2 H
OH + H 2N OMe St Ne1 OMe 01-' OMe Se1NNH H 2 J OMe 18 19 20 n-Hex' 0 O C0 2H 0 Step2 NN H H 10
Step 1 tert-Amyl alcohol (1195 pL, 10.99 mmol) was added to Compound 18 (99.6 mg, 0.392 mmol), N-hydroxysuccinimide (54.3 mg, 0.472 mmol), 1-hydroxybenzotriazole monohydrate (6.3 mg, 0.041 mmol) and 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (99.8 mg, 0.521 mmol), and the mixture was stirred at °C. The reaction mixture was cooled to room temperature, and acetic acid (7.1 mg, 0.12 mmol), compound 19 (99.2 mg, 0.513 mmol) and diazabicycloundecene (155.9 mg, 1.024 mmol) were added. The mixture was stirred at room temperature for 3 hours minutes. Water (1100 pL) and toluene (500 pL) were added to isolate the aqueous layer. Water (200 pL) and 25% aqueous sodium hydroxide solution (20 pL) were added to the organic layer. The layers were separated, and the aqueous layer was isolated. The obtained aqueous layers were combined, and toluene (500 JIL) was added. The aqueous layer was isolated and concentrated under reduced pressure to obtain an aqueous solution of compound 20.
Step 2 To the aqueous solution of compound 20 were added acetonitrile (1000 PL) and concentrated hydrochloric acid (200 pL), and the mixture was stirred at 45°C and then allowed to stand overnight at room temperature. The mixture was concentrated under reduced pressure, and water (500 iL), formic acid (10 pL), 25% aqueous sodium hydroxide solution (180 pL), acetonitrile (300 pL) and methanol (3000 pL) were added. The mixture was concentrated to about half volume under reduced pressure. Seed crystals were added to precipitate, and the mixture was further concentrated under reduced pressure and allowed to stand overnight at room
AQ temperature. The obtained solid was collected by filtration and washed with water to obtain Compound 10 (23.0 mg, 16.1%).
[00841 The diastereomer ratio of a: b = 20: 1 was obtained in the intramolecular cyclization reaction of the step for preparing Compound 9 in Example 1. The diastereomer ratio of a: b = 67: 3 was obtained in the intramolecular cyclization reaction of the step for preparing Compound 10 in Example 7.
[0085] Thus, the intramolecular cyclization reaction as described herein proceeds with high diastereoselectivity, so that an optically active compound of the formula (VII) can be synthesized efficiently.
[00861 Example 8 Br OMe
N-,,OH 23 OMe O~e OMee H 2N OH Ph N OH 23 Step 1 Step 2 Ph N"- OMe Step 3 21 22 24 OMe OMe Ph IN"OMe Step4 H 2 N1\1- OMe Step 5 salt of 26
25 26 O Bn, Bn, OH0 0 0 00 0 0 N 0N 26 N OMe satt of _ 3.H N ' Ste NON4' -\14N
Q ,NH Step 6 NH 0 Step 7 H =H H H 27 Boc 28 Boc MeO OMe F S S or F (VIlla) (IXa)
Step 1 to Step 3 Benzaldehyde (4.16 g, 38.43 mmol) was dissolved in 1,2-dimethoxyethane (10 mL), and Compound 21 (2.35 g, 38.42 mmol) was added dropwise over about 30 minutes with stirring at about 25°C. The reaction mixture was stirred for 20 minutes. The resulting reaction mixture was ice-cooled, and sodium tert-pentoxide (8.46 g,76.82 mmol) and 1,2-dimethoxyethane (10 mL) were added to the reaction mixture. Compound 23 (8.45 g, 49.94 mmol) was then added, and the mixture was stirred at °C for 13 hours. To the resulting reaction mixture was added sodium borohydride (2.91 gm, 76.92 mmol) and further methanol (19.69 g, 614.45 mmol) dropwise. The mixture was stirred at the same temperature for 30 minutes. To the mixture was added slowly demonized water (20 mL), and then 20% aqueous hydrochloric acid was added until the pH became 2. Subsequently, isopropyl acetate (50 mL) was added, and the pH was adjusted to 10 with 20% aqueous sodium hydroxide and extracted with isopropyl acetate (50 mL). The obtained organic layer was washed with 20% aqueous sodium chloride, dried over anhydrous sodium sulfate, and concentrated. Toluene (50 mL) was added to the concentrated solution, and the mixture was concentrated again to obtain Compound 25 (4.07 g, 44%). 1H-NMR (CDC3) : 2.82 (2H, t, J=5.28Hz), 3.38 (6H, s), 3.50 (2H, d, J=5.16Hz), 3.63 (2H, t, J=5.28Hz), 3.81 (2H, s), 4.50 (H, t, J=5.24Hz), 7.29-7.34 (5H, m)
Step 4 The mixture of 53.5% water-wet 5% Pd/C (3.01 g), Compound 25 (7.00 g, 29.25 mmol), THF (70 mL) and acetic acid (1.76 g, 29.25 mmol) was degassed under reduced pressure and then subjected to hydrogen replacement twice. The mixture was stirred at 450 C for 4 hours under hydrogen pressure of 0.3 to 0.2 Mpa. The mixture was filtered, washed four times with THF (30 mL), and concentrated to obtain Compound 26.
Step 5 THF was added to the obtained Compound 26, and then, an acid was added dropwise at about 25°C to evaluate whether the compound crystallized or not. The results of the evaluation for crystallization and the property of the obtained crystals are shown in Table 1 below.
Table 1 Acid Crystallization Phosphoric Acid Yes LNo deliquescence MsOH Yes Deliquescent 4-Cl-PhCOOH Yes Deliquescent TsOH No AcOH No PhCOOH No PhSO 3H No 4-MeOPhCOOH No Hydrochloric Acid No Colored Sulfuric Acid No Colored
Crystallization of phosphate salt To a solution of Compound 26 in THF (13.6 mL) was added slowly 85% phosphoric acid (3.37 g, 29.25 mmol) at about 25°C to precipitate phosphate salt of Compound 26. The resulting suspension was cooled to about 5C and then filtered. The obtained solid was washed three times with THF (15 mL) and dried under reduced pressure at about 40°C to obtain crystals of phosphate salt of Compound 26 (6.57 g, 91%). 1H-NMR (DMSO-D6) : 2.86 (2H, t, J=5.62Hz), 3.29 (6H, s), 3.43 (2H, d, J=5.14Hz), 3.59 (2H, t , J=5.62Hz), 4.48 (H, t, J=5.14Hz)
The results of X-ray powder diffraction are shown below in terms of the angle 20(°) of diffraction peaks.
n
Table 2 Relative Intensity 5.10 100 10.16 1 15.32 9 20.46 28 21.82 1 25.66 11 30.92 5 36.26 1
As shown above, crystallization of Compound 26 was evaluated, and phosphate salt, methanesulfonate salt and p-chlorobenzoate salt thereof were crystallized. Especially, crystals ofphosphate salt are excellent as they were not deliquescent. In addition, crystals ofphosphate salt ofCompound 26 enable to avoid extraction ofthe compound with dichloromethane, so that it makes easier to handle.
Step 6 A solution containing Compound 27 (50.00 g, 133.55 mmol) and 20% sodium hydroxide (80.13 g, 400.65 mmol) in THF (100 mL) was stirred at 55°C for 5 hours. The reaction mixture was concentrated. Water (34.6 g)and THF (50 mL) were added to the obtained residue. The mixture was heated to 50°C, and the organic layer and aqueous layer were separated. The aqueous layer was concentrated (132.54 g). The resulting concentrate (79.52 g, 80.13 mmol) was further concentrated to 69.11 g. The concentrate was added to a suspension of the phosphate salt of Compound 26 (23.77 g, 96.16 mmol) in acetonitrile (300 mL) at 0°C. Then, 1 hydroxybenzotriazole monohydrate (2.45 g, 16.00 mmol), WSCD - HC1 (18.43 g, 96.14 mmol) and acetonitrile (540 mL) were added, and the mixture was stirred at 50°C for 8 hours. The reaction mixture was concentrated to 144.71 g, and isopropyl acetate (300 mL) and water (60 mL) were added, and the mixture was extracted. The organic layer was washed three times with 20% aqueous sodium chloride and concentrated. Insoluble matter was removed by filtration, and the obtained filtrate was concentrated to 60.46 g. Isopropyl acetate was added to the concentrate, and the mixture was stirred at 22°C for 30 minutes to obtain a suspension of Compound 28. To the resulting suspension was added n-heptane (90 mL), followed by filtration, and the filtrate was washed three times with 30 mL of a mixed solution (heptane: isopropyl acetate = 2: 1 (v/v)). The obtained solid was dried to obtain Compound 28 (33.61 g, 85%).
Step 7 Compounds of the formula (VIIla) and the formula (IXa) were obtained according to the methods as described in W02012/039414 and W02016/175224.
[00871 Example 9 n-Hex,, n-Hex, n-Hex, 0 n-Hex... 0 0r0O0 0H Step 1 Br Step 2 OH Step 3
29 30 31 32 Step 1 Under a nitrogen atmosphere, Compound 29 (105 mg, 0.5 mmol) was dissolved in ethyl acetate (5 mL), and N-bromosuccinimide (196 mg, 1.1 mmol) and AIBN (33 mg, 0.2 mmol) were added. The mixture was heated to reflux for 7 hours with stirring. After cooling to room temperature, ethyl acetate (10 mL) and saturated aqueous sodium hydrogen carbonate (5 mL) were added. The organic layer was separated, washed with saturated brine (5 mL), and dried with anhydrous sodium sulfate. The solvent was removed under reduced pressure, and the residue was purified by silica gel column chromatography (hexane/ethyl acetate = 75: 25 to 70:30) to obtain Compound 30 (126 mg, 87%). 1H-NMR (CDC3): 0.90 (t, J=7.0 Hz, 3H), 1.25-1.51 (m, 6H), 1.71-1.79 (in, 2H), 4.21 (t, J=6.8 Hz, 2H), 4.41 (s, 2H), 6.38 (d, J=5.8 Hz, 1H), 7.68 (d, J=5.6 Hz, 1H).
Step 2 Compound 30 (58 mg, 0.2 mmol) was dissolved in a mixed solution of acetonitrile (1.2 mL) and water (1.2 mL) under nitrogen atmosphere, and then, calcium carbonate (40 mg, 0.4 mmol) was added. The mixture was stirred at 85°C for 24 hours. After cooling the mixture to room temperature, water (5 mL) and ethyl acetate (10 mL) were added. The organic layer was separated and washed with saturated brine (5 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 50: 50) to obtain Compound 31 (37 mg, 83%). 1H-NMR (CDCl3) 8: 0.79-0.86 (in, 3H), 1.19-1.34 (m, 6H), 1.61-1.68 (m, 2H), 4.04 (t, J=6.8 Hz, 2H), 4.56 (d, J=6.1 Hz, 2H), 6.31 (d, J=5.6 Hz, 1H), 7.66 (d, J=5.6 Hz, 1H).
Step 3 Under a nitrogen atmosphere, Compound 31 (45 mg, 0.2 mmol) was dissolved in a mixed solution of acetonitrile (0.9 mL) and water (0.45 mL), and then, TEMPO (1.6mg, 0.01 mmol), sodium hydrogen carbonate (17 ing, 0.2 mmol), KBr (24 mg, 0.2 mmol) and NaClO•5H 2 0 (72 mg, 0.44 mmol) were added. After stirring for 2 hours at room temperature, 15% aqueous Na2S203 solution (2 mL) and ethyl acetate (10 mL) were added. The organic layer was separated, washed with water (5mL) and saturated brine (5 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (chloroform/methanol = 100: 0 to 80:20) to give Compound 32 (48mg, 99%). 1H-NMR (CDCl3) 8: 0.90 (t, J=7.1 Hz, 3H), 1.26-1.42 (in, 6H), 1.78-1.85 (in, 2H), 4.59 (t, J=7.0 Hz, 2H) 6.51 (d, J=5.6 Hz, 1H), 7.84 (d, J=5.8 Hz, 1H)
[0088] Example 10
Bn, 0Bn,s Bn,0 0O n0 BnO Bns 0
OEt OEt Step 1 Step 2 '., OH Step 3 O't Me O 33 34 NMe 2 NMe 2 35 36
Step 1 To a solution of Compound 33 (91 mg, 0.5 mmol) in DMSO (0.5 mL) were added dimethylformamide dimethylacetal (0.133 mL, 1.0 mmol) and acetic acid (9 mg, 0.15 mmol) under a nitrogen atmosphere. The mixture was stirred at 85°C for 24 hours. After cooling the mixture to room temperature, ethyl acetate (10 mL) and water (5 mL) were added. The organic layer was separated and washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate : 30 to 10:90) to obtain Compound 34 (79 mg, 72%). 1H-NMR (CDCl3) 6: 2.84 (s, 3H), 3.10 (s, 3H), 4.04 (s, 2H), 4.60 (s, 2H), 5.40 (d, J=12.7 Hz, 1H), 7.26-7.39 (in, 5H), 7.71 (d. J=12.7 Hz, 1H).
Step 2 To a solution of Compound 34 (110 mg, 0.5 mmol) in toluene (2.2 mL) were added diethyl oxalate (219 mg, 1.5 mmol) and 20 wt% sodium ethoxide in ethanol (0.29 mL, 0.75 mmol). The mixture was stirred at room temperature for 1 hour. To the mixture were added 10% aqueous ammonium chloride (5 mL) and ethyl acetate (10 mL). The organic layer was separated, washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 70: to 50:50) to obtain Compound 35 (154 mg, 96%). 1H-NMR (CDC3) 6: 1.34 (t, J = 7.2 Hz, 3H), 2.81 (s, 3H), 3.17 (s, 3H), 4.33 (q, J=7.2 Hz, 2H), 4.83 (s, 2H), 5.43 (d, J=12.4 Hz, 1H), 7.32-7.39 (in, 3H), 7.45 (d, J=7.0 Hz, 2H), 7.78 (d. J=12.4 Hz, 1H).
Step 3 To a solution of Compound 35 (32 mg, 0.1 mmol) in N,N-dimethylacetamide (1 mL) was added pyridinium p-toluenesulfonate (75 mg, 0.3 mmol) under nitrogen atmosphere. The mixture was stirred at 60°C for 1 hour. Water (5 mL) and ethyl acetate (10 mL) were added to the reaction mixture. The organic layer was separated and washed with water (5 mL) and saturated brine (5 mL), dried over anhydrous sodium sulfate and evaporated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 80: 20 to 70:30) to obtain Compound 36 (26 mg, 97%).
[0089] Example 11
OH n-Hex, 0 n-Hexs 0 n-Hex,0 n-Hex,0 01z 1, .~ -O " 0N z ,CHO-01",OO Step 1 Step 2 Step 3 Step4 OH
37 38 39 40 32
Step 1 Under a nitrogen atmosphere, a suspension of potassium carbonate (8.22 g, 59.5 mmol) in DMA (25 mL) was heated at 78°C with stirring. Tothesuspension was added dropwise a solution of maltol (5.00 g, 39.6 mmol) and 1-bromohexane (6.68 mL, 47.6 mmol) in DMA (50 mL) over 1 hour. The mixture was heated at 78°C for 3 hours with stirring. After cooling the mixture to 40°C., 1-ethylpiperazine (1.52 mL, 11.9 mmol) was added. The reaction mixture was heated to 70 0 C and stirred with heating for 1 hour, and then cooled to 40°C. Ethyl acetate (50 mL) and water (100 mL) were added to the reaction mixture, and the mixture was extracted with ethyl acetate (20 mL). The organic layer was separated, washed twice with 0.4 mol/L hydrochloric acid (20 mL) and once with 5% aqueous sodium hydrogen carbonate (20 mL), dried over anhydrous sodium sulfate, and evaporated under reduced pressure to give Compound 38 (8.15 g, 98%). 1H-NMR (CDCl3) 6: 0.84-0.93 (in, 3H), 1.29-1.45 (in, 6H), 1.67-1.74 (in, 2H), 2.32 (s, 3H), 4.04 (t, J = 6.8 Hz, 2H), 6.34 (d, J = 5.6 Hz, 1H), 7.60 (d, J = 5.6 Hz, 1H).
Step 2 Under a nitrogen atmosphere, to a solution of the crude product of Compound 38 (1.00 g, 4.76 mmol) in DMSO (5.00 mL) were added dimethylformamide dimethylacetal (3.41 mL, 25.5 mmol), propionic acid (0.076 mL, 1.02 mmol) and triethylamine (0.424 mL, 3.06 mmol), and the mixture was heated at 100°C for 19 hours with stirring. After cooling the reaction mixture to room temperature, toluene (10 mL) and 10% aqueous NaCl solution (20 mL) were added, and the mixture was extracted with toluene (10 mL). The organic layer was washed twice with water (10 mL), and anhydrous sodium sulfate (1.00 g) and activated carbon (200 mg) were added. The mixture was stirred at room temperature for 1 hour, filtered through KC-flock and washed with toluene (30 mL). The filtrate was concentrated under reduced pressure to give Compound 39 (1.30 g, 100%). 1H-NMR (CDCl3) 6 : 0.89 (t, J= 7.2 Hz, 3H), 1.29-1.35 (in, 4H), 1.41-1.48 (in, 2H), 1.68-1.76 (in, 2H), 2.94 (s, 6H), 4.03 (t, J = 6.8 Hz, 2H), 5.22 (d, J = 13.3 Hz, 1H), 6.19 (d, J = 5.6 Hz, IH), 7.12 (d, J = 13.3 Hz, 1H), 7.42 (d, J = 5.6 Hz, 1H).
Step 3 Under a nitrogen atmosphere, sodium periodate (32.8 g, 154 mmol) was dissolved in water (122 mL) and acetonitrile (82 mL), and the mixture was heated at °C with stirring. To the reaction mixture was added the crude product of Compound 39 (8.15 g, 30.7 mmol) in acetonitrile (82 mL) dropwise over 2 hours and minutes. The mixture was heated at 45°C for 1 hour with stirring, filtered through KC-flock, and washed with ethyl acetate (200 mL). The filtrate was washed with 7.7% aqueous sodium chloride (106 mL), 10% aqueous sodium thiosulfate (250 mL) and 5% aqueous sodium hydrogen carbonate (82 mL). Each aqueous layer was extracted with ethyl acetate (82 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure to obtain Compound 40 (6.26 g, 91%). 1H-NMR (CDCl3) 6 : 0.90 (t, J = 7.0 Hz, 3H), 1.28-1.44 (m, 6H), 1.72-1.80 (in, 2H), 4.46 (t, J = 6.7 Hz, 2H), 6.47 (d, J = 5.8 Hz, 1H), 7.76 (d, J = 5.8 Hz, 1H), 10.19 (s, 1H).
Step 4 To a solution of the crude product of Compound 40 (6.88 g, 30.7 mmol) in acetonitrile (73 mL) were added acetic acid (2.63 mL, 46.1 mmol) and 30% aqueous hydrogen peroxide (7.84 mL, 76.8 mmol) with ice-cooling under nitrogen atmosphere. An aqueous solution (73 mL) containing 80% sodium chlorite (7.64 g, 67.5 mmol) was added dropwise over 23 minutes, and the mixture was stirred at room temperature for 2 hours. Diisopropyl ether (73 mL) and 5% aqueous sodium hydrogen carbonate (73 mL) were added to the reaction solution, and the mixture was extracted with 5% aqueous sodium hydrogen carbonate (73 mL). To the aqueous layer were added 5% aqueous sodium bisulfite (73 mL) and diisopropyl ether (73 mL), and the mixture was extracted with 5% aqueous sodium hydrogen carbonate solution (73 mL). Ethyl acetate (73 mL) and 2 mol/L hydrochloric acid (146 mL) were added to the obtained aqueous layer, and the mixture was extracted with ethyl acetate (73 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. Diisopropyl ether (37 mL) was added, and the mixture was stirred at room temperature for 1 hour. The precipitated solid was filtered and washed with diisopropyl ether (36 mL) to obtain Compound 32 (4.45 g, 60%). 1H-NMR (CDCl3) 6 : 0.89 (t, J= 6.9 Hz, 3H), 1.31-1.41 (m, 7H), 1.78-1.85 (in, 2H), 4.58 (t, J = 6.9 Hz, 2H), 6.51 (d, J = 5.6 Hz, 1H), 7.84 (d, J 5.6 Hz, 1H).
[0090] Example 12 Bn,0Bns Bns Bn,0 0 o - N, 0 CoHO 0 OH 0 Step1 Step 2 Step 3 O O 41 42 43 44
Step 1 To a solution of Compound 41 (1.00 g, 4.62 mmol) in DMSO (5 mL) were added dimethylformamide dimethylacetal (3.10 mL, 23.1 mmol) and N,N,N-trimethylglycine (108 mg, 0.925 mmol) under nitrogen atmosphere. The mixture was heated at 100°C for 8 hours with stirring. After cooling the reaction mixture to room temperature, toluene (10 mL) and 10% aqueous NaCl solution (20 mL) were added. The mixture was extracted with toluene (10 mL). The organic layer was washed twice with water (10 mL) and concentrated under reduced pressure to 1.53 g. Toluene (1.5 mL) was added to the residue, and the mixture was stirred at 0°C for 15 minutes. To the solution was added diisopropyl ether (30 mL), and the mixture was stirred at 0°C for minutes. The precipitated solid was filtered and washed with a mixed solvent (21 mL) of toluene/diisopropyl ether (1:20) to obtain Compound 42 (987 mg, 79%).
1H-NMR (CDCl3) 6 : 2.83 (s, 6H), 5.01 (d, J = 13.4 Hz, 1H), 5.11 (s, 2H), 6.22 (d, J =.8 Hz, 1H), 7.03 (d, J = 13.4 Hz, 1H), 7.29-7.35 (in, 3H), 7.42 (d, J = 5.8 Hz, 1H), 7.44-7.47 (in, 2H).
Step 2 To a solution of Compound 42 (2.00 g, 7.37 mmol) in acetonitrile (30 mL) was added dropwise an aqueous solution (30 mL) of sodium periodate (3.47 g, 16.2 mmol) over 16 minutes with ice-cooling under nitrogen atmosphere. The reaction mixture was stirred at room temperature for 5 hours, filtered through KC-flock and washed with ethyl acetate (40 mL). Water (20 mL) was added to the filtrate. The organic layer was separated and washed with 10% aqueous sodium thiosulfate (20 mL) and % aqueous sodium hydrogen carbonate (20 mL). Each aqueous layer was extracted with ethyl acetate (20 mL). The organic layer was dried over anhydrous sodium sulfate and concentrated under reduced pressure. The residue was purified by silica gel column chromatography (hexane/ethyl acetate = 80: 20 to 50:50) to obtain Compound 43 (1.62 g, 95%). 1H-NMR (CDC13) 5 : 5.52 (s, 2H), 6.50 (d, J = 5.8 Hz, 1H), 7.33-7.40 (in, 5H), 7.75 (d, J = 5.8 Hz, 1H), 9.88 (s, 1H).
Step 3 To a solution of Compound 43 (1.78 g, 7.74 mmol) in acetonitrile (18 mL) were added TEMPO (121 mg, 0.774 mmol) and 5% aqueous sodium hydrogen carbonate (10.7 mL) under nitrogen atmosphere. The reaction mixture was ice-cooled, and 5% aqueous sodium hypochlorite (12.4 mL) was added dropwise over 8 minutes. The mixture was stirred at room temperature for 2.5 hours. To the reaction mixture were added diisopropyl ether (36 mL) and 5% aqueous sodium bicarbonate (18 mL), and the mixture was extracted with 5% aqueous sodium hydrogen carbonate (18 mL). To the aqueous layer were added 5% aqueous sodium bisulfite (18 mL) and diisopropyl ether (36 mL), and the mixture was extracted with 5% aqueous sodium hydrogen carbonate (18 mL). To the aqueous layer was added 2 mol/L hydrochloric acid (36 mL), and the mixture was stirred for 30 minutes under ice cooling. The precipitated solid was filtered and washed with water (72 mL) to obtain Compound 44 (1.08 g, 57%). 1H-NMR (CDCl3) 6: 5.65 (s, 2H), 6.53 (d, J = 5.8 Hz, 1H), 7.39-7.41 (m, 5H), 7.82 (d, J = 5.8 Hz, 1H).
[0091] Thus, the process for preparing a pyrone derivative according to the present invention can produce the pyrone derivative in more industrially suitable and efficient manner with avoiding use of a toxic reagent or a cryogenic reaction, and therefore it enables to produce a compound having a common skeleton in more industrially suitable and efficient manner.
[0092] Example 13 n-Hex' 0 O n-Hex' 0 O n-Hex' O 0 Stepi1 Step 2 0-A 0 1O 0 , OH OH , 1O O O s 1 NH 'N'NH2 45 46 47
Step 1 Water (2644 mg) was added to compound 45 (660.8 mg, 2.75 mmol) and ammonium acetate (2120 mg, 27.5 mmol), and the mixture was stirred at 85°C for 7.5 hours. After standing at room temperature overnight, the mixture was further stirred at 85°C for 7.5 hours and allowed to stand at room temperature overnight. The reaction solution was heated to 600 C, and insoluble material formed during the reaction was separated by decantation. The insoluble material was washed with water (2000 pL), and the washing solution was combined with the reaction solution. Acetonitrile (700 pL) was added to the obtained solution, and the pH was adjusted to 2 by adding conc. hydrochloric acid. The precipitated solid was separated by filtration, washed with water, and dried under reduced pressure to obtain Compound 46 (649.3 mg, 99%). 1 H-NMR (DMSO-d6) 6 : 0.87 (t, J = 7.0 Hz, 3H), 1.25-1.31 (in, 4H), 1.31-1.40 (in, 2H), 1.58-1.66 (in, 2H), 4.00 (t, J = 6.6 Hz, 2H), 6.51 (br, 1H), 7.70 (br, 1H), 12.21 (br, 1H).
Step 2 Compound 46 (110 mg, 0.460 mmol) and potassium hydroxide (135 mg, 2.41 mmol) were dissolved in a mixture of water (1480 1 L) and tert-amyl alcohol (110 pL). To the mixture was added hydroxylamine-O-sulfonic acid (101 mg, 0.894 mmol) at room temperature over 2 hours and 20 minutes. The mixture was stirred for 1 hour and 30 minutes and allowed to stand at room temperature overnight. The reaction mixture was stirred at room temperature, and potassium hydroxide (20.3 mg, 0.362 mmol), water (129 pL) and hydroxylamine-O-sulfonic acid (10.3 mg, 0.0911 mmol) were added, and the mixture was stirred for 2 hours. Thereafter, hydroxylamine-O sulfonic acid (5.1 mg, 0.045 mmol) was added, and the mixture was stirred for 2.5 hours. Water (330 pL) was added to the reaction mixture, and the pH was adjusted to 1 by adding 10% hydrochloric acid. The obtained solid was separated by filtration, washed with water, and dried under reduced pressure to obtain compound 47 (98.9 mg, 85%). 1H-NMR (DMSO-d6) 6: 0.86 (t, J = 7.0 Hz, 3H), 1.21-1.36 (m, 6H), 1.51-1.58 (in, 2H), 3.99 (t, J = 6.6 Hz, 2H), 6.18 (d, J = 7.2 Hz, 1H), 7.54 (d, J = 7.2 Hz, 1H).
[00931 As described above, the disclosed process for the production of an aminopyridone derivative can efficiently produce the aminopyridone derivative, and thus, efficiently produce a compound having a common partial skeleton in more industrially suitable manner.
Industrial Applicability
[00941 The present invention is useful as a process for preparing substituted polycyclic pyridone derivatives having a cap-dependent endonuclease inhibitory activity and its intermediates.
[0095] Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.
[0096] The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.
ro
Claims (27)
1. A process for preparing a compound of the formula (VII), or a salt thereof: R ',. 0 0
O N (VII)
N H H
wherein R 1 is hydrogen or a protecting group for hydroxyl group; X is 0 or CH 2 ; the process comprising removing -RA from a compound of the formula (IV):
R1O 0 RA1 2 ON N RA
N'N_ H H RA3
wherein R 1 is hydrogen or a protecting group for hydroxyl group; RA1 is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is an optionally protected carboxy group; and the carbon atom to which RA is bound is optically active; provided that one of RA1, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH 2, or RA1, RA2 and RA3 are hydrogen and X is CHRA.
2. A process for preparing a compound of the formula (IV), or a salt thereof:
R1O 0 RA1 O N RA 2
N'N_ H H RA3
wherein each symbol is as defined below; the process comprising subjecting a compound of the formula (III) to an intramolecular cyclization reaction:
R0O 0 RA2
H R8 ON , 7 R RR 3 RA
wherein R 1 is hydrogen or a protecting group for hydroxyl group; RA1 is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is an optionally protected carboxy group; and the carbon atom to which RA is bound is optically active; provided that one of RA1, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH 2, or RA1, RA2 and RA3 are hydrogen and X is CHRA; R 7 is NH 2 or NHR 2 ; R 2 is a protecting group for amino group; R 8 is -CHO or CH(OR4)(OR4); R 4 is each independently hydrogen or a protecting group deprotectable by an acid, or two R 4 may be taken together to form a ring.
3. The process for preparing the compound of the formula (VII) or a salt thereof according to claim 1, which comprises the process according to claim 2.
4. The process according to claim 2 or 3, wherein the intramolecular cyclization reaction is carried out in the presence of an acid.
5. A process for preparing a compound of the formula (III) or a salt thereof:
R0. 0 A2
R H R8 N , 7 R RA 3
wherein each symbols is as defined below; the process comprising reacting a compound of the formula (Ia):
N_ OH (1a) 1 N OR 70
wherein R 1 is hydrogen or a protecting group for hydroxyl group; R 7 is NH 2 or NHR 2 ; R 2 is a protecting group for amino group; with a compound of the formula (II): RA1
H2 N X YRS
RA 3
wherein RA1 is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is an optionally protected carboxy group; and the carbon atom to which RA is bound is optically active; provided that one of RA1, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH 2 , or RA1, RA2 and RA3 are hydrogen and X is CHRA; R 8 is -CHO or -CH(OR4)(OR4); R4 is each independently hydrogen or a protecting group deprotectable by an acid, or two R 4 may be taken together to form a ring.
6. A process for preparing a compound of the formula (IV) or a salt thereof:
'O 0 RA1
Ot N RA 2
N'N H H RA3 wherein each symbol is as defined below; the process comprising subjecting a compound of the formula (VI) to an intramolecular cyclization reaction: R 1, 0 0 0 R3
NNH (VI) 3 RA N'R5 X RA1 2 RA
wherein R 1 is hydrogen or a protecting group for hydroxyl group; RA1 is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is an optionally protected carboxy group; and the carbon atom to which RA is bound is optically active; provided that one of RA1, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH 2, or RA1, RA2 and RA3 are hydrogen and X is CHRA; R 3 is a protecting group for carboxyl group; R 5 is hydrogen or a protecting group for amino group.
7. The process for preparing the compound of the formula (VII) or a salt thereof according to claim 1, which comprises the process according to claim 6.
8. The process according to claim 6 or 7, wherein the intramolecular cyclization reaction is carried out in the presence of a base.
9. A process for preparing a compound of the formula (VI) or a salt thereof:
0 0
ONHOR (VI) N' 5 R RA X RA1 2 RA
wherein each symbol is as defined below; the process comprising reacting a compound of the formula (Ib):
R R O4 ' R3 (Ib)
n iuNH2
wherein R1 is hydrogen or a protecting group for hydroxyl group; R3 is a protecting group for carboxylgroup; with a compound of the formula (V): 6 O'R RA3 R N (V) X RA1
RA2
wherein R 5 is a protecting group for amino group; R 6 is substituted or unsubstituted alkyl, or substituted or unsubstituted aromatic carbocyclyl; RA1 is hydrogen or RA; RA2 is hydrogen or RA; RA3 is hydrogen or RA; X is 0, CH 2 or CHRA; RA is an optionally protected carboxy group; and the carbon atom to which RA is bound is optically active; provided that one of RA1, RA2 and RA3 is RA, the other two are hydrogen, and X is 0 or CH 2, or RA1, RA2 and RA3 are hydrogen and X is CHRA.
10. A process for preparing a compound of the formula (X3) or a salt thereof:
Rla
O" ' OH (X3) NO
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (X):
Rla 0 O (X)
wherein Ria is a protecting group for hydroxyl group except optionally substituted aromatic carbocyclylalkyl and optionally substituted aromatic heterocyclylalkyl, with a halogenating agent to obtain a compound of the formula (Xl):
Rla0
Z1 (X1)
wherein Z1 is halogen, and the other symbols are as defined above; (Step 2) reacting the compound of the formula (X1) with hydroxide ion to obtain a compound of the formula (X2):
Rla
O N OH (X2) NO
wherein each symbol is as defined above; and (Step 3) reacting the compound of the formula (X2) with an oxidizing agent to obtain the compound of the formula (X3).
11. The process according to claim 10, wherein the halogenating agent is NBS, NCS, NIS, Br, C12, 12or DBDMH, and the solvent in Step 1 is methyl acetate, ethyl acetate, propyl acetate or acetonitrile.
12. The process according to claim 10 or 11, wherein the oxidizing agent is sodium hypochlorite.
13. A process for preparing a compound of the formula (X8) or a salt thereof:
R lb 0 0 O' 0 OH (X8) 0
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (X4):
Rib'O
(X4)
wherein Rib is a protecting group for hydroxyl group, with a compound of the formula:
RB RB I I|+ RD NsRB (X5) or NsRB (X5')
RD RD
wherein each RB is independently alkyl optionally substituted by a group selected from Substituent Group E, or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group E, or the two RB may be taken together with an adjacent nitrogen atom to form a heterocycle optionally substituted by a group selected from Substituent Group E; each RD is independently alkyloxy or dialkylamino; Substituent Group E comprises halogen, hydroxy, sulfanyl, amino, alkyl, haloalkyl, alkyloxy, alkylsulfanyl, alkylsilyl, aromatic carbocyclylsilyl optionally substituted by a group selected from Substituent Group F, carbocyclyl optionally substituted by a group selected from Substituent Group F, heterocyclyl optionally substituted by a group selected from Substituent Group F, a carbocyclylalkyloxy optionally substituted by a group selected from Substituent Group F, heterocyclylalkyloxy optionally substituted by a group selected from Substituent Group F, carbocyclylalkylsulfanyl optionally substituted by a group selected from Substituent Group F, heterocyclylalkylsulfanyl optionally substituted by a group selected from Substituent Group F, carbocyclylalkylamino optionally substituted by a group selected from Substituent Group F, heterocyclylalkylamino optionally substituted by a group selected from Substituent Group F, carbocyclyloxy optionally substituted by a group selected from Substituent Group F, heterocyclyloxy optionally substituted by a group selected from Substituent Group F, haloalkyloxy, alkyloxyalkyl, alkyloxyalkyloxy, alkyloxycarbonylamino, alkylamino, alkylcarbonylamino, alkylsulfonyl and alkylsulfonylamino; Substituent Group F comprises halogen, hydroxy, amino, oxo, nitro, alkyl, haloalkyl, alkyloxy and a protecting group for amino group; to obtain a compound of the formuala (X6):
0 R RB (X6)
wherein each symbol is as defined above; (Step 2) reacting the compound of the formula (X6) with an oxidizing agent to obtain a compound of the formula (X7):
R b O
H (X7) O1--
wherein each symbol is as defined above; and (Step 3) reacting the compound of the formula (X7) with an oxidizing agent to obtain the compound of the formula (X8).
14. The process according to claim 13, wherein the Step 1 is carried out in the presence of a base.
15. The process according to claim 13 or 14, wherein the oxidizing agent in Step 2 is sodium periodate.
16. A process for preparing a compound of the formula (V4) or a salt thereof:
o O 0 'R 3 (V4)
-0
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (X9):
o (X9)
wherein Ri is hydrogen or a protecting group for hydroxyl group, with a compound of the formula:
RC RC l+ RD N,Rc (Vi) or NRc (V1
RD RD wherein each RC is independently alkyl optionally substituted by a group selected from Substituent Group E, or aromatic carbocyclyl optionally substituted by a group selected from Substituent Group E, or the two RC may be taken together with an adjacent nitrogen atom to form a heterocycle optionally substituted by a group selected from Substituent Group E; each RD is independently alkyloxy or dialkylamino; Substituent Group E is as defined above in claim 13 to obtain a compound of the formula (V2):
RNV V.RCe (V2) N _0 Rc wherein the wavy line represents E- or Z-form or a mixture thereof, and the other symbols are as defined above; and (Step 2) subjecting the compound of the formula (V2) to intramolecular cyclization reaction by reacting with a compound of the formula (V3): 0
Z27"Y OR3 (V3) 0 wherein R 3 is alkyl optionally substituted by a group selected from Substituent Group E, aromatic carbocyclylalkyl optionally substituted by a group selected from Substituent Group B; and Z2 is hydrogen, halogen or alkyloxy optionally substituted by a group selected from Substituent Group E, to obtain a compound of the formula (V4).
17. The process according to claim 16, wherein the Step 1 is carried out using DMSO as a solvent in the presence of an additive agent.
18. The process according to claim 16 or 17, wherein the intramolecular cyclization reaction is carried out in the presence of an acid under anhydrous condition.
19. A process for preparing a compound of the formula (V7) or a salt thereof: R1, 0 0
3a (V7) H -R 01 N -. H O
wherein each symbol is as defined below, comprising reacting a compound of the formula (V6):
R 1,0 0 O O'R3a (V6)
NH
wherein RIis hydrogen or a protecting group for hydroxyl group; and R3 ais hydrogen or a protecting group for carboxyl group with a hydroxylamine derivative.
20. A process for preparing a compound of the formula (V7) or a salt thereof: R1, 0 0
3a (V7) H -R 01N NH O
wherein each symbol is as defined below, comprising (Step 1) reacting a compound of the formula (V5):
O O'R3a (V5)
wherein R 1 is hydrogen or a protecting group for hydroxyl group, and Ra is hydrogen or a protecting group for carboxyl group with ammonia to obtain a compound of the formula (V6):
R-O O O aR3a (V6)
NH
wherein each symbol is as defined above; and (Step 2) reacting the compound of the formula (V6) with a hydroxylamine derivative to obtain the compound of the formula (V7).
21. The process according to claim 19 or 20, wherein the reaction with a hydroxylamine derivative is carried out in the presence of a base.
22. The process according to any one of claims 19 to 21, wherein the hydroxylamine derivative is hydroxylamine-O-sulfonic acid or 0-(2,4 dinitrophenyl)hydroxylamine.
23. A process for preparing a compound of the formula (VIIIa) or the formula (IXa): 0 OH O
N O I N,kN O N H H (Villa) N, NO (IXa)
F or
F SFF F s
which comprises the process according to any one of claims 1 to 22.
24. A compound of the formula (III) or a salt thereof: RO O,0 RA1 O RA
H,, x R8 3 RA
wherein each symbol is as defined in claim 2.
25. A compound of the formula (VI) or a salt thereof: R 1, 0 0 N HOR3
NH (VI) 3 RA NR5 X RA1 2 RA
wherein each symbol is as defined in claim 6.
26. A compound of the formula (IV) or a salt thereof:
R1O 0 RA1 O N RA 2
N'N H H RA3
wherein each symbol is as defined in claim 1.
27. A compound of the formula (VII), (IV), (III), (VI), (X3), (X8), (V4), (V7) or (VIIIa) or a salt of any of the foregoing prepared using the process of any one of claims 1 to 23.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-195802 | 2017-10-06 | ||
JP2017195802 | 2017-10-06 | ||
PCT/JP2018/037390 WO2019070059A1 (en) | 2017-10-06 | 2018-10-05 | Method for stereoselectively producing substituted polycyclic pyridone derivative |
Publications (2)
Publication Number | Publication Date |
---|---|
AU2018344739A1 AU2018344739A1 (en) | 2020-04-30 |
AU2018344739B2 true AU2018344739B2 (en) | 2023-04-13 |
Family
ID=65995109
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2018344739A Active AU2018344739B2 (en) | 2017-10-06 | 2018-10-05 | Stereoselective process for preparing substituted polycyclic pyridone derivatives |
Country Status (13)
Country | Link |
---|---|
US (2) | US11286262B2 (en) |
EP (1) | EP3693373A4 (en) |
JP (1) | JP6924839B2 (en) |
KR (1) | KR20200066644A (en) |
CN (1) | CN111386276B (en) |
AR (1) | AR113748A1 (en) |
AU (1) | AU2018344739B2 (en) |
BR (1) | BR112020006639A2 (en) |
CA (1) | CA3078442A1 (en) |
IL (1) | IL273821B2 (en) |
MX (1) | MX2020003469A (en) |
SG (1) | SG11202002789XA (en) |
WO (1) | WO2019070059A1 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11261198B2 (en) | 2016-06-20 | 2022-03-01 | Shionogi & Co., Ltd. | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
BR112020021059B1 (en) | 2018-04-24 | 2022-08-30 | Shionogi & Co., Ltd | SOLID DOSAGE FORM |
CN111484508B (en) * | 2019-01-29 | 2022-11-25 | 北京四环制药有限公司 | Compound for preparing balsalavir or derivatives thereof, preparation method and application thereof |
CN111662263B (en) * | 2019-03-07 | 2022-08-12 | 广东东阳光药业有限公司 | Preparation method of pyrone compound |
CN111825699B (en) * | 2019-04-15 | 2023-02-21 | 上海复星星泰医药科技有限公司 | Sulfur-containing heterocyclic compounds and process for producing the same |
CN109912553A (en) * | 2019-04-19 | 2019-06-21 | 山东百诺医药股份有限公司 | A kind of intermediate and preparation method thereof |
CN110105372B (en) * | 2019-06-05 | 2022-05-10 | 南京焕然生物科技有限公司 | Preparation method of R-7- (benzyloxy) -tetrahydro-1H-oxazine pyrido-triazine-6, 8-diketone |
CN112707862B (en) * | 2019-10-24 | 2022-09-27 | 广东东阳光药业有限公司 | Preparation method of polycyclic pyridone compound |
CN111057070A (en) * | 2019-10-30 | 2020-04-24 | 浙江工业大学 | Synthesis method of baroxavir key intermediate |
CN111205304B (en) * | 2020-03-02 | 2022-03-11 | 南京法恩化学有限公司 | Preparation method of Barosavir intermediate |
RU2745985C1 (en) * | 2020-05-07 | 2021-04-05 | Андрей Александрович Иващенко | Anticoronavirus therapeutic agent - substituted 7-hydroxy-3,4,12,12a-tetrahydro-1h-[1,4]oxazino[3,4-c]pyrido[2,1-f][1,2,4]triazine-6,8-dione for the prevention and treatment of covid-19 |
TWI796701B (en) * | 2020-05-28 | 2023-03-21 | 太景生物科技股份有限公司 | Stereoselective synthesis of intermediate for preparation of heterocyclic compound |
CN112409379B (en) * | 2020-09-28 | 2023-07-28 | 长沙晶易医药科技股份有限公司 | Deuterated dihydrodibenzothiazepine compound and pharmaceutical composition containing same |
JPWO2022107755A1 (en) | 2020-11-17 | 2022-05-27 | ||
CN112592330A (en) * | 2020-12-14 | 2021-04-02 | 陕西师范大学 | Synthesis method of 2-aldehyde thiochromone compound |
CN113072454B (en) * | 2021-04-09 | 2022-03-04 | 南京正济医药研究有限公司 | Novel crystal form of oxoethylamine compound |
CN113845502A (en) * | 2021-11-29 | 2021-12-28 | 山东诚创蓝海医药科技有限公司 | Preparation method of 3- (benzyloxy) -4-oxo-4H-pyran-2-carboxylic acid |
CN114014874B (en) * | 2021-12-20 | 2023-04-28 | 中国科学院上海药物研究所 | Preparation method of Mabalo Sha Wei intermediate |
CN114409623A (en) * | 2021-12-30 | 2022-04-29 | 和鼎(南京)医药技术有限公司 | Method for preparing baroxavir intermediate |
CN114315957B (en) * | 2021-12-30 | 2023-07-07 | 深圳瑞德林生物技术有限公司 | Preparation method of polypeptide |
CN114436879A (en) * | 2022-01-14 | 2022-05-06 | 海南三帝制药有限公司 | Preparation method of trimethylcaine hydrochloride |
CN116082361B (en) * | 2023-04-11 | 2023-06-13 | 和鼎(南京)医药技术有限公司 | Method for preparing Marbalo Sha Wei intermediate and Marbalo Sha Wei |
CN116423599B (en) * | 2023-05-29 | 2024-06-25 | 德华兔宝宝装饰新材股份有限公司 | Antibacterial flame-retardant wood veneer and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016175224A1 (en) * | 2015-04-28 | 2016-11-03 | 塩野義製薬株式会社 | Substituted polycyclic pyridone derivative and prodrug thereof |
WO2017104691A1 (en) * | 2015-12-15 | 2017-06-22 | 塩野義製薬株式会社 | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6426418B1 (en) * | 2001-11-02 | 2002-07-30 | Apotex, Inc. | Processes for the manufacturing of 3-hydroxy-N,1,6-trialkyl-4-oxo-1,4-dihydropyridine-2-carboxamide |
LT3284520T (en) | 2005-04-28 | 2019-09-25 | Viiv Healthcare Company | Polycyclic carbamoylpyridone derivative having hiv integrase inhibitory activity |
US20100098640A1 (en) | 2005-06-20 | 2010-04-22 | Cohen Seth M | Multidentate Pyrone-Derived Chelators for Medicinal Imaging and Chelation |
EP2330902B1 (en) | 2008-07-25 | 2012-11-14 | GlaxoSmithKline LLC | Chemical compounds |
WO2010011818A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
SI2320908T1 (en) | 2008-07-25 | 2014-05-30 | Viiv Healthcare Company | Dolutegravir Prodrugs |
WO2010011819A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
KR101772610B1 (en) | 2008-07-25 | 2017-09-12 | 비이브 헬쓰케어 컴퍼니 | Chemical compounds |
WO2010011815A1 (en) | 2008-07-25 | 2010-01-28 | Smithkline Beecham Corporation | Chemical compounds |
IT1392249B1 (en) | 2008-11-28 | 2012-02-22 | Univ Degli Studi Urbino | DERIVATIVES OF [(3-HYDROXY-4-PYRON-2-IL) METHYL] -AMINE AND THEIR USE AS ANTI-NEOPLASTIC DRUGS |
KR101663222B1 (en) | 2008-12-11 | 2016-10-06 | 시오노기세야쿠 가부시키가이샤 | Maltol ether processes and intermediates |
JP5572168B2 (en) | 2008-12-11 | 2014-08-13 | ビーブ・ヘルスケア・カンパニー | Process for producing carbamoylpyridone HIV integrase inhibitor and intermediate |
WO2010068253A1 (en) | 2008-12-11 | 2010-06-17 | Shionogi & Co., Ltd. | Synthesis of carbamoylpyridone hiv integrase inhibitors and intermediates |
TWI518084B (en) | 2009-03-26 | 2016-01-21 | 鹽野義製藥股份有限公司 | Process for pyrone and pyridone derivatives |
DK2444400T3 (en) | 2009-06-15 | 2018-06-18 | Shionogi & Co | SUBSTITUTED POLYCYCLIC CARBAMOYLPYRIDONE DERIVATIVE |
AU2011221037A1 (en) | 2010-02-26 | 2012-09-06 | Japan Tobacco Inc. | 1,3,4,8-tetrahydro-2H-pyrido[1,2-a]pyrazine derivative and use of same as HIV integrase inhibitor |
PT2602260T (en) | 2010-08-05 | 2016-12-27 | Shionogi & Co | Process for preparing compound having hiv integrase inhibitory activity |
PT2620436T (en) | 2010-09-24 | 2018-09-28 | Shionogi & Co | Substituted polycyclic carbamoyl pyridone derivative prodrug |
US9714243B2 (en) | 2012-12-17 | 2017-07-25 | Merck Sharp & Dohme Corp. | 4-pyridinonetriazine derivatives as HIV integrase inhibitors |
PT3608325T (en) | 2012-12-21 | 2022-10-17 | Gilead Sciences Inc | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use |
US10087178B2 (en) | 2012-12-27 | 2018-10-02 | Japan Tobacco Inc. | Substituted spiropyrido[1,2-a]pyrazine derivative and medicinal use thereof as HIV integrase inhibitor |
WO2014128545A2 (en) | 2013-02-19 | 2014-08-28 | Aurobindo Pharma Limited | An improved process for the preparation of dolutegravir |
WO2015009927A1 (en) | 2013-07-17 | 2015-01-22 | Ratiopharm Gmbh | Dolutegravir salts |
WO2015019310A1 (en) | 2013-08-07 | 2015-02-12 | Mylan Laboratories Ltd | Process for the preparation of dolute-gravir and intermediates thereof |
WO2015039348A1 (en) | 2013-09-23 | 2015-03-26 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2015089847A1 (en) | 2013-12-20 | 2015-06-25 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2015110897A2 (en) | 2014-01-21 | 2015-07-30 | Laurus Labs Private Limited | Novel process for the preparation of dolutegravir and pharmaceutically acceptable salts thereof |
WO2015177537A1 (en) | 2014-05-20 | 2015-11-26 | Cipla Limited | Process for preparing polycyclic carbamoyl pyridone derivatives and intermediates thereof |
WO2015199167A1 (en) | 2014-06-25 | 2015-12-30 | 日本たばこ産業株式会社 | METHOD FOR PRODUCING SUBSTITUTED SPIROPYRIDO[1,2-a]PYRAZINE DERIVATIVE, AND INTERMEDIATE |
EP3229804B1 (en) | 2014-12-09 | 2020-05-06 | Merck Sharp & Dohme Corp. | Spirocyclic heterocycle compounds useful as hiv integrase inhibitors |
WO2016092527A1 (en) | 2014-12-12 | 2016-06-16 | Sun Pharmaceutical Industries Limited | A process for the preparation of dolutegravir |
KR20170113650A (en) | 2015-02-06 | 2017-10-12 | 밀란 래버러토리스 리미티드 | Manufacturing method of dolutegravir |
US10590922B2 (en) | 2015-08-20 | 2020-03-17 | Haug Sauer Kompressoren Ag | Reciprocating piston compressor, a retrofit kit for a reciprocating piston compressor and the use of a connecting rod in a reciprocating piston compressor |
EP3377065B1 (en) * | 2015-11-17 | 2022-05-18 | Merck Sharp & Dohme Corp. | Spirocyclic pyridotriazine derivatives useful as hiv integrase inhibitors |
US11261198B2 (en) | 2016-06-20 | 2022-03-01 | Shionogi & Co., Ltd. | Process for preparing substituted polycyclic pyridone derivative and crystal thereof |
AU2017310774B2 (en) * | 2016-08-10 | 2023-01-19 | Shionogi & Co., Ltd. | Substituted polycyclic pyridone derivative and pharmaceutical composition containing prodrug thereof |
CA3088926A1 (en) | 2018-01-17 | 2019-07-25 | Jiangxi Caishi Pharmaceutical Technology Co., Ltd. | Pyridone derivative, composition and use as antiviral drug thereof |
-
2018
- 2018-10-05 EP EP18865221.8A patent/EP3693373A4/en active Pending
- 2018-10-05 SG SG11202002789XA patent/SG11202002789XA/en unknown
- 2018-10-05 CA CA3078442A patent/CA3078442A1/en active Pending
- 2018-10-05 US US16/652,122 patent/US11286262B2/en active Active
- 2018-10-05 KR KR1020207011759A patent/KR20200066644A/en not_active Application Discontinuation
- 2018-10-05 AU AU2018344739A patent/AU2018344739B2/en active Active
- 2018-10-05 CN CN201880072447.6A patent/CN111386276B/en active Active
- 2018-10-05 BR BR112020006639-7A patent/BR112020006639A2/en unknown
- 2018-10-05 AR ARP180102884A patent/AR113748A1/en unknown
- 2018-10-05 JP JP2019547031A patent/JP6924839B2/en active Active
- 2018-10-05 MX MX2020003469A patent/MX2020003469A/en unknown
- 2018-10-05 WO PCT/JP2018/037390 patent/WO2019070059A1/en unknown
-
2020
- 2020-04-05 IL IL273821A patent/IL273821B2/en unknown
-
2022
- 2022-02-24 US US17/679,449 patent/US20230040262A1/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016175224A1 (en) * | 2015-04-28 | 2016-11-03 | 塩野義製薬株式会社 | Substituted polycyclic pyridone derivative and prodrug thereof |
WO2017104691A1 (en) * | 2015-12-15 | 2017-06-22 | 塩野義製薬株式会社 | Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug |
Also Published As
Publication number | Publication date |
---|---|
IL273821B (en) | 2022-12-01 |
BR112020006639A2 (en) | 2020-09-24 |
KR20200066644A (en) | 2020-06-10 |
IL273821B2 (en) | 2023-04-01 |
AU2018344739A1 (en) | 2020-04-30 |
EP3693373A1 (en) | 2020-08-12 |
SG11202002789XA (en) | 2020-04-29 |
CN111386276B (en) | 2023-06-23 |
JP6924839B2 (en) | 2021-08-25 |
EP3693373A4 (en) | 2021-11-03 |
US11286262B2 (en) | 2022-03-29 |
US20200247818A1 (en) | 2020-08-06 |
CN111386276A (en) | 2020-07-07 |
US20230040262A1 (en) | 2023-02-09 |
MX2020003469A (en) | 2020-08-03 |
AR113748A1 (en) | 2020-06-10 |
CA3078442A1 (en) | 2019-04-11 |
IL273821A (en) | 2020-05-31 |
WO2019070059A1 (en) | 2019-04-11 |
JPWO2019070059A1 (en) | 2020-10-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018344739B2 (en) | Stereoselective process for preparing substituted polycyclic pyridone derivatives | |
AU640549B2 (en) | Hexa-cyclic compound | |
RU2728829C1 (en) | New isoindoline derivative, pharmaceutical composition including thereof and use thereof | |
AU2008305767B2 (en) | Process for the synthesis of E1 activating enzyme inhibitors | |
JP6234471B2 (en) | Synthesis of spirocyclic isoxazoline derivatives | |
KR102630010B1 (en) | Tricyclic heterocyclic compounds useful as inhibitors of TNF | |
JP6779899B2 (en) | Heterocyclic compounds useful as TNF inhibitors | |
ES2866073T3 (en) | Pyridin-2-one fused tricyclic derivatives and their use as BRD4 inhibitors | |
CN112300153B (en) | Heterocyclic compound, pharmaceutical composition and application | |
CA3083938A1 (en) | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | |
CN114364676B (en) | Novel tricyclic aromatic heterocyclic compound, preparation method, pharmaceutical composition and application thereof | |
AU2013253541A1 (en) | Quinazolinedione derivative | |
AU2022389558A1 (en) | Kif18a inhibitor | |
AU2020346172A1 (en) | Aromatic heterocyclic compound having tricyclic structure, and preparation method therefor and application thereof | |
EP4249077A1 (en) | Novel acridinium salt and method for producing same | |
CN115403511A (en) | Piperlongumine analogue, pharmaceutical composition, preparation method and application thereof | |
CN114901639B (en) | HBV inhibitors and uses thereof | |
AU2006244916B2 (en) | Method for producing indole derivative having piperidine ring | |
CN115772159A (en) | KIF18A inhibitors | |
BRPI0708560A2 (en) | process for preparing a compound, and, compound | |
CN113912567A (en) | Process for producing glucopyranosyl derivative and intermediate therefor | |
AU2013204601B2 (en) | Process for the synthesis of E1 activating enzyme inhibitors | |
CN115073425A (en) | Compound serving as TBK1 inhibitor, pharmaceutical composition containing compound and application of compound | |
KR20150130327A (en) | Substituted (r)-3-(4-methylcarbamoyl-3-fluorophenylamino)tetrahydrofuran-3-ene-carboxylic acid(variants) and ester thereof, method for producing and using same | |
RU2478637C2 (en) | METHOD FOR PREPARING 5,8,9,10-TETRAHYDROPYRIMIDINO[4,5-d]AZOCINE DERIVATIVES HAVING TRIFLATE, SECONDARY AND TERTIARY AMINO GROUPS IN 4-TH POSITION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ STEREOSELECTIVE PROCESS FOR PREPARING SUBSTITUTED POLYCYCLIC PYRIDONE DERIVATIVES |
|
DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO REMOVE HAKOGI, TOSHIKAZU |
|
DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ OKAMOTO, KAZUYA; UENO, TATSUHIKO; HATO, YOSHIO AND MAJIMA, SHOHEI |
|
FGA | Letters patent sealed or granted (standard patent) | ||
GD | Licence registered |
Name of requester: HOFFMANN-LA ROCHE INC. Name of requester: F. HOFFMANN-LA ROCHE LTD |